

チャールズ・メダワー／アニタ・ハードン著

## 暴走するクスリ？

抗うつ剤と善意の陰謀

## 参考文献リスト

NPO 法人医薬ビジランスセンター(NPOJIP)発行の日本語版  
(吉田篤夫/浜六郎/別府宏圀訳)には参考文献を割愛しました  
ので、必要の方はこのリストを参照ください。

## References

- ABC-TV "Primetime" program: Influencing doctors – How pharmaceutical companies use enticement to 'educate' physicians, 21 February 2002.
- ABPI – Association of the British Pharmaceutical Industry, Code of Practice for the Pharmaceutical Industry, 1st edition, 1958–2003.
- *Compendium of Data Sheets and Summaries of Product Characteristics* 1974–2000, London: Datapharm publications.
- ABPI spokesman, Richard Lay, quoted in Meek C., Fraud & misconduct in medical research, *Health Which?* December 2001, 21–24.
- Press Release: European proposals on medicines information for public flawed, says ABPI, 25 June 2002.
- Press Release, Audit report on regulatory authority welcomed by industry, 16 January 2003.
- Press release, Guidance on disease awareness campaigns, 24 April 2003.
- Mission statement, [www.abpi.org.uk](http://www.abpi.org.uk) 2003.
- Abraham J., Sheppard J., *The Therapeutic Nightmare: the battle over the world's most controversial sleeping pill*, London: Earthscan, 1999.
- Agelink M.W., Zitselsberger A., Kleiser E., Withdrawal symptoms after discontinuation of Venlafaxine (letter), *Am. J. Psychiatry*, 154, 10, October 1997, 1473–1474.
- Aitken M., Holt F., A prescription for direct drug marketing, *The McKinsey Quarterly*, 22 March 2000, 82.
- "Alaniz13" – Message board response, posted 10:16 PST, 24 February 2002 in response to ABC-TV "Primetime" program, 2002.
- Alexander E.J., Withdrawal effects of sodium amytal, *Dis. Nerv. Sys*, 1951, 12, 77–82.
- AMA – American Medical Association, Health literacy: Report of the Council on Scientific Affairs, *JAMA*, 1999, 281, 552–557.
- American Psychiatric Association, *Diagnostic and Statistical Manual of Mental Disorders*, 3rd edition, Washington DC: APA, 1980.
- Task Force on Benzodiazepine Dependency. *Benzodiazepine Dependence, Toxicity, and Abuse*. Washington DC: APA, 1990.
- *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition, Washington DC: APA, 1994.
- (Online public information), *Electroconvulsive Therapy (ECT)*, published April 1997 at <http://www.psych.org/public-info/ECT-1.HTM>
- Amsden G.W., Georgian F., Orthostatic hypotension induced by sertraline withdrawal, *Pharmacotherapy*, 1996, 16, 4, 684–686.
- Anderson I.M., Tomenson, B.M., Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic anti-depressants: a meta-analysis. *Brit Med J* 1995; 310, 3 June: 1433–8.
- Angell M., Is academic medicine for sale? *N Engl J Med* 2000, 18 May; 342: 1516–1518.

- Conversation: Open science or junk science, *The American Prospect*, 2000 June 5, 14, 11.
- Angell M., Relman A. S., Prescription for profit, *Washington Post*, 20 June 2001, Page A27.
- Anstie F.E., Physiological and therapeutical action of alcohol, *Lancet*, 23 September 1865, 343.
- Antonuccio D.O., Danton W.G., DeNelsky G.Y., Greenberg R.P., Gordon J.S., Raising questions about antidepressants, *Psychotherapy and Psychosomatics* 1999, 68: 1, 3-14.
- Appleton W.S., *Prozac and the new antidepressants*, New York: Plum, 1997.
- D'Arcy P. F., Epidemiological aspects of iatrogenic disease, in D'Arcy P.F. & Griffin J.P. (eds), *Iatrogenic Diseases* (3rd Ed), Oxford: OUP, 1986), 29-58.
- Arlington S., *Pharma 2005: The challenges, presentation to the American Society for Clinical Pharmacology and Therapeutics*, PriceWaterhouseCoopers, 2001.
- Arno P., Davis M., Paying twice for the same drugs, *Washington Post*, 27 March 2002, A21.
- Arya D.K., Withdrawal after discontinuation of paroxetine (letter), *Aust NZ J Psychiatry*, October 1996, 30 (5), 702.
- Åsberg M., Schalling D., Traskman-Bendz L., Wagner A., Psychobiology of suicide, impulsivity, and related phenomena, in Melzer H.Y. (ed.), *Psychopharmacology: the third generation of progress*, New York: Raven Press, 1987, 655-668.
- Ashton H., Dangers and medico-legal aspects of benzodiazepines, *J. Med. Defence Union*, Summer 1987, 6-8.
- Asch S., Effects of Group Pressure Upon the Modification and Distortion of Judgments. In Harold S. Guetzkow (ed.), *Groups, Leadership and Men*. New York: Russell and Russell, 1963, pp. 177-190.
- Ashton H., Young A.H., Ferrier N., Psychopharmacology revisited, (comment on Healy and Tranter, 1999) *J Psychopharmacol.*, 1999, 13 (3), 296-298.
- Asscher W.A., Strategy of risk-benefit analysis, in D'Arcy P.F., Griffin J.P. (eds) 1986, 108-116.
- Statement made at a meeting organised by the Campaign for Freedom of Information (Committee room 6, House of Commons) 29 April 1993.
- Atlanta Journal-Constitution: Editorial: Drugmakers' cash packs wallop, 14 October 2002, cited at [www.bamcoalition.org/News/HW/10.14.02.htm](http://www.bamcoalition.org/News/HW/10.14.02.htm)
- Ayd F.J., *Recognising the Depressed Patient, with Essentials of Management and Treatment*, New York, Grune, 1961.
- The discovery of antidepressants, interview with D. Healy in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 179.
- *Lexicon for Psychiatry, Neurology and Neuroscience*, Williams & Wilkins, Baltimore, 1996(b).
- Baer L., Ricciardi J., Keuthen N., Pettit A.R., Buttolph M.L., Otto M., Minichiello W., Jenike M.A., Discontinuing obsessive-compulsive disorder medication with behavior therapy (letter), *Am. J. Psychiatry*, December 1994, 151 (12), 1842.
- Baglione J., FDA effort to halt drugs from Canada stirs uproar, *Wall Street Journal*, 13 March 2003.
- Bain & Co., Has the pharmaceutical blockbuster model gone bust? Reposted in *Business Wire* (New York), 8 December 2003.
- Bakker A., Severe withdrawal symptoms with fever upon stopping paroxetine (letter, in Dutch), *Ned Tijdschr Geneeskde*, 28 August 1999, 143 (35), 1795, discussion 1795-6.

- Baldessarini R.J., Drugs and the treatment of psychiatric disorders, in Goodman L.S., Gilman A. (eds), *The Pharmacological Basis of Therapeutics* (6th Edition). New York: Macmillan, 1980, 435.
- Viguera A.C., Tondo L., Discontinuing psychotropic agents, (comment on Healy and Tranter, 1999) *J Psychopharmacol.*, 1999, 13 (3), 292-293.
- Viguera A.C., Relapse of depressive symptoms after discontinuing sertraline (letter, plus response), *JAMA*, July 28 1999, 282 (4), 323-324.
- Ban T.A., They used to call it psychiatry, interview with D. Healy in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 589.
- Bangemann H. (European Commissioner: chair), Second Round Table, *Completing the Single Pharmaceutical Market*, Frankfurt, 8 December 1997.
- Barbui C., Hotopf M., Forty years of antidepressant drug trials (review article), *Acta Psychiatr. Scand*, 2001, 104, 92-95.
- Bardelay D., email to Ewen M., 8 April 2002.
- Barr L.C., Goodman W.K., Price L.H., Physical symptoms associated with paroxetine discontinuation (letter). *Am J Psychiatry* 1994 Feb, 151 (2), 289.
- Barsky A.J., The paradox of Health, *N Engl J Med.* 1988 Feb 18; 318 (7): 414-8.
- Bass A., Drug companies enrich Brown Professor, *The Boston Globe*, 4 October 1999, A1.
- Beaumont G., The place of clomipramine in psychopharmacology, interview with D. Healy in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 327.
- Beasley C.M., Dornseif B.E., Bosomworth J.C., Saylor M.E., Rampey A.H., Heiligstein J.H. et al., Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression, *Brit. Med. J.*, 1991, 303, 685-692.
- Beasley C.M., Suicidality with fluoxetine, *CNS Drugs* 1998, 9, 513-514.
- Belkin L., Prime time pushers, *Mother Jones*, March/April 2001.
- Belloeuf L., Le Jeune C., Hugues F.C., Paroxetine withdrawal syndrome [Article in French], *Ann Med Interne (Paris)* 2000 Apr; 151 Suppl. A: A52-3.
- Benazzi F., Venlafaxine withdrawal symptoms, *Can. J. Psychiatry*, September 1996, 41, 487.
- SSRI discontinuation syndrome related to fluvoxamine, *J Psychiatry & Neuroscience*, 1998, 23, (2), 94.
- Nefazodone withdrawal symptoms, *Can. J. Psychiatry*, March 1998, 43: 2, 194-195. — SSRI discontinuation syndrome treated with fluoxetine (letter), *Int J Geriatr Psychiatry* 1998 June, 13: 6, 421-2.
- Sertraline discontinuation syndrome presenting with severe depression and compulsions, *Biol. Psychiatry*, 1998, 43, 929-930.
- Bennett J.R. (Chairman, Campaign on the restriction and use of the barbiturates), Barbiturate Abuse, circular letter to doctors, May 1976.
- Benson H., *Timeless Healing: The Power and Biology of Belief*, Simon and Schuster, 1996.
- Berbehenn E., Lurie P., Stolley P., Wolfe S.M., Petition to the FDA to Ban the Anti-depressant Drug Nefazodone (SERZONE), Health Research Group publication #1657, 6 March 2003.
- Berlin C.S., Fluoxetine withdrawal symptoms. *J Clin Psychiatry* 1996 Feb, 57 (2), 93-4.
- Berridge V., Professionalisation and narcotics: the medical and pharmaceutical professions and British narcotic use, 1868-1926. *Psychological Medicine*, 1978, 8, 361-372.
- Bhuamik S., Wildgust H.J., Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders (letter), *Human Psychopharmacology*, 1996, 11, 337-338.

- Black D.W., Wesner R., Gabel J., The abrupt discontinuation of fluvoxamine in patients with panic disorder. *J Clin Psychiatry* 1993 Apr, 54 (4), 146-9.
- Black K., Shea C., Dursun S., Kutcher S., Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria, *J Psychiatry Neuroscience*, 2000, 25 (3), 255-261.
- Blacker R., Clare A., Depressive disorder in primary care, *Br. J. Psychiatry*, 1987, 150, 737-751.
- Blackwell B., Simon J.S., Antidepressant Drugs, in M.N.G. Dukes (ed.), *Meyler's Side Effects of Drugs*, 11th ed., Amsterdam, Elsevier, 1988, 27-76.
- Blair T., Speech on open government, Campaign for Freedom of Information's annual Awards ceremony, 25 March 1996.
- Foreword: PICTF, 2001.
- Blau N., Time to let the patient speak, *BMJ* 1989 Jan 7; 298 (6665): 39.
- Bloch M., Stager S.V., Braun A.R., Rubinow D.R., Severe psychiatric symptoms associated with paroxetine withdrawal. *Lancet* 1995 Jul 1, 346 (8966), 57.
- Blomgren S.L., Krebs W., Wilson M., Ascroft R., Fava R.M., Rosenbaum J., SSRI Dose Interruption Study: Interim Data, *American Psychiatric Association, 150th-Annual-Meeting*, San-Diego, 1997.
- BMJ* (Anon), Today's drugs – Drugs of Addiction 2, *Brit. Med. J.*, 31 October 1964, 1119-1120.
- (Anon), Benzodiazepine addicts to sue, *Brit. Med. J.*, 26 January 1991, 302, 2000.
- BNF – Joint Formulary Committee, *British National Formulary*, London British Medical Association, Royal Pharmaceutical Society of Great Britain, published twice yearly.
- Bodenheimer T., Uneasy alliance: clinical investigators and the pharmaceutical industry. *N Engl J Med* 2000; 342:1539-1544.
- *Conflict of Interest in Clinical Drug Trials: A Risk Factor for Scientific Misconduct* (Department of Health and Human Services, Office for Human Research Protections, August 15, 2000), available at <http://ohrp.osophs.dhhs.gov/coi/bodenheimer.htm>
- Bogetto F., Bellino S., Revello R.B., Patria L., Discontinuation syndrome in dysthymic patients with SSRIs: a clinical investigation, *CNS Drugs*, 2002, 16, 4, 273-283.
- Bohaychuck W., Ball G., *Conducting GCP Compliant Clinical Research* (Chichester and New York: Wiley, 1999).
- Boseley S., Medical studies 'rubbish', *The Guardian*, 24 June 1998, 5.
- Drug firm asks public to insist NHS buys its product, *The Guardian*, 29 September 1999.
- Murder, suicide. A bitter aftertaste for the 'wonder' depression drug, *The Guardian*, 11 June 2001.
- Bitter pill, *The Guardian*, 21 May, 2002.
- Drug firm issues addiction warning, *The Guardian*, 23 January 2002, 5.
- Scientist in rethink over drug link to suicide, *The Guardian*, 1 October 2003.
- Bowe C., us drug regulator slams European pricing, *Financial Times*, 25 September 2003.
- Boyd E.A., Cho M.K., Bero L., Financial conflict-of-interest-policies in clinical research: Issues for clinical investigators, *Academic Medicine*, 2003, 78, 769-774.
- Boyd I.W., Venlafaxine withdrawal reactions, *Med. J. Aust.*, 1998, July 20, 169 (2), 91-92.
- Bracewell M., Escape capsule, *The Observer* (Life section), 7 November 1993, 30-31.
- Brandt W. (Chairman) et al., *North South: A Programme for Survival* (London: Pan, 1981).
- Brecher E.M., *Licit and Illicit Drugs*, Mount Vernon, NY: Consumers Union, 1973.

- Breggin P.R., A case of fluoxetine-induced stimulant side-effects with suicidal ideation associated with a possible withdrawal reaction ("crashing"), *Int. J. Risk & Safety in Medicine*, 1992, 3, 325-328.
- Breggin P.R., Breggin G.R., *Talking back to Prozac*, New York: St. Martin's, 1994.
- P. Brown, Drug regulation – a life sentence on the industry? *Scrip Magazine*, Sept 1996, 23-24.
- Brunel P., Vial T., Roche I., Bertolotti E., Evreux J.C., Follow-up of 151 pregnant women exposed to antidepressant treatment (excluding MAOIs) during organogenesis (translation of title in French), *Therapie*, March-April 1994, 49 (2), 117-122.
- Brunet P. (Head of Pharmaceuticals Unit, DG Enterprise), letter to Bas van der Heide, (Coordinator, Health Action International), 4 July 2000.
- Letter to *Social Audit*, 20 February 2002.
- Letter to *Social Audit*, 2 April 2002.
- Bülow-Olsen A. (Chair, Danish Migraine Association), personal communication (CM), November 2000.
- Brown G. (UK Chancellor of the Exchequer), Drugs are just the start, *The Guardian*, 28 August 2003, 25.
- Brown P., Drug regulation – a life sentence on the industry? *Scrip Magazine*, Sept 1996, 23-24.
- Bryois C., Rubin C., Zbinden J.D., Baumann P., [Withdrawal syndrome caused by selective serotonin reuptake inhibitors: apropos of a case]. In German. *Schweiz Rundsch Med Prax*, 4 March 1998, 87:10, 345-348.
- Byck R., Drugs and the treatment of psychiatric disorders, in L.S. Goodman, A. Gilman (eds), *The Pharmacological Basis of Therapeutics* (5th Edition). New York: Macmillan, 1975, 187.
- Byrne S.E., Rothschild A.J., Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. *J. Clin. Psychiatry* 1998, 59, 279-288.
- Cabinet Office, *Code of Practice on Access to Government Information* (2nd Edition), and *Guidance Notes* (2nd Edition); London, 1997. See: Department for Constitutional Affairs website, <http://www.dca.gov.uk/foi/codpracgi.htm>
- Campbell E.G., Weissman J.S., Clarrige B., Yucel R., Causino N., Blumenthal D., Characteristics of medical school faculty members serving on institutional review boards: Results of a national survey, *Academic Medicine*, 2003, 78, 831-836.
- Campomori A., Brambilla P., Barbui C., Safety of Selective Serotonin Re-uptake Inhibitors, Unpublished review, 1999.
- Carpenter G., (citing Kass T.), Campaigning for awareness, *Pharmafocus*, 2 June 2003.
- Carranza E.J., Rivas-Vazquez R.A., Rey J.A., Rey G.J., SSRI discontinuation and buspirone, *Am J Psychiatry*, June 2001, 158 (6), 966-967.
- Castagnoli W.G., The coming showdown on DTC, *Medical Marketing and Media magazine*, September 1998.
- Castafieda R., Levy R., Westreich L.M., et al., Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents. *J Clin Psychiatry* 1996 Oct, 57 (10), 485-6.
- Cauchon D., FDA advisers tied to industry, *USA Today*, 24 September, 2000.
- CBC – Canadian Broadcasting Corporation, News and Current Affairs interview transcript, 12 June 2001.
- CBS-TV Network sales, A study of attitudes, concerns and information needs for prescription drugs and related illness, (New York, CBS, June 1984).

- Cetera P., Pharmaceutical Marketing: this means war. *Pharmaceutical Executive*, July 1992, 50-58.
- CDC – Centers for Disease Control and Prevention (US Department of Health and Human Services), Prevalence of healthy lifestyle characteristics – Michigan, 1998 and 2000, *Morbidity and Mortality Weekly Report*, 2001; 50, 758-761.
- CDER (Center for Drug Evaluation & Research, FDA), Approval package, Paxil CR (paroxetine hydrochloride), 16 February 1999.
- Annual Adverse Drug Experience Report, 30 October 1997.
- Office of Drug Safety Annual report, FY 2001, 2002.
- Preventable Adverse Drug Reactions: A Focus on Drug Interactions (2002).
- Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L., Birth outcomes in pregnant women taking fluoxetine, *New Eng J Medicine*, 3 October 1996, 335, 14, 1010-1015.
- CFOI – Campaign for Freedom of Information. See [www.cfoi.org.uk](http://www.cfoi.org.uk)
- Chang K., Tobacco industry fought drugs' marketing, *New York Times*, 14 August 2002.
- Chaput de Saintonge D.M., Herxheimer A., Harnessing placebo effects in health care, *Lancet*, 1994 Oct 8; 344(8928): 995-8.
- Charatan F., US drug companies help pay for Bush inauguration, *Brit Med J*, 2001; 322: 192.
- Chouinard G., Saxena B., Bélanger M.-C., Ravindran A., Bakish D., Beauclair L., Morris P., Vasavan Nair N.P., Manchanda R., Reesal R., Remick R., O'Neill M.C., A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder, *J. Affective Disorders*, 54, 1999, 39-48.
- Clark K., Parliamentary debate: Opren, *Hansard*, 27 January 1983, cols 1106-1130.
- Clift A.D., Factors leading to dependence on hypnotic drugs, *Brit Med J*, 1972, 3, 614-617.
- Cohen J.S., Overdose – The case against the drug companies, New York: Jeremy P. Tarcher/Putnam, 2001.
- Cole J.O., Therapeutic efficacy of antidepressant drugs, A review. *JAMA*, 1964 Nov 2, 190 (5), 124-131.
- Evaluation of psychotropic drugs, interview in D. Healy, *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996.
- Committee on the Review of Medicines, Systematic Review of the Benzodiazepines. *Br Med J*, 29 March 1980, 910-912.
- Conan Doyle A., The Science of Deduction in *The Sign of Four* (First published in Nov. 1887 as the main part of Beeton's Christmas Annual. The first book edition by Ward, Lock & Co. in July 1888. The first American edition was published by J. B. Lippincott Co. in 1890. Full text is available on many websites, notably: [http://homepages.uis.edu/JRBURGESS/Sherlock\\_The%20Sign\\_Of\\_Four.html](http://homepages.uis.edu/JRBURGESS/Sherlock_The%20Sign_Of_Four.html)
- Congress Watch: America's other drug problem – A briefing book on the Rx Drug debate. (Washington DC: Public Citizen, 2002).
- Consumers Union: Backgrounder: *The Pharmaceutical Industry and Consumers – Key Factors Affecting Affordability of Prescription Drugs* (Washington DC: Consumers Union, February 2003).
- Cooper G.L., The safety of fluoxetine – an update, *Br J Psychiatry*, 1988, 153 (suppl 3), 77-86.
- Coppen A., Biological psychiatry in Britain, interview in D. Healy, *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 279, 265-286.

- Cornwell J., *The Power to Harm – mind, medicine and murder on trial*, London: Viking, 1996.
- Costei A.M., Kozer E., Ho T., Ito S. Koren G., Perinatal outcome following third trimester exposure to Paroxetine, *Arch Pediatr Adolesc Med*, 2002; 116:1129-1132.
- Coupland N.J., Bell C.J., Serotonin reuptake inhibitor withdrawal, *J. Clin. Psychopharmacol*, 1996, 16, 3, 356-362.
- Cowley G., Springen K., Leonard E.A., Robbins K., Gordon J., The promise of Prozac, *Newsweek*, 26 March 1990, 42-45.
- Croasdale M., CME providers gear up to comply with PhRMA code, *AMNews* (American Medical Association) 7 October 2002.
- Cross J., Lee H., Westelinck A., Nelson J., Grudzinskas C., Peck C., Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999, *Pharmacoepidemiology and Drug Safety*, 2002 September, 11 (6), 439-446.
- Crossman R.H.S., Parliamentary debate on Thalidomide, 8 May 1963.
- Cunningham L.A. for the Venlafaxine XR 208 Study Group, Once-daily venlafaxine Extended Release (XR) and venlafaxine Immediate Release (IR) in outpatients with major depression, *Ann Clin Psychiatry*, 1997, 9, 3, 157-164.
- CSM – Committee on Safety of Medicines, Annual Reports, London: Medicines Commission/Department of Health, 1987-1992.
- Committee on Safety of Medicines, Medicines Control Agency, Benzodiazepines, dependence and withdrawal symptoms, *Current Problems in Pharmacovigilance*, No 21, London: CSM/MCA, January 1988, 1-2.
- Minutes of CSM meeting of 26 March 1998, item 7.3.3
- Fluvoxamine (Faverin): Adverse reaction profile. *Current Problems in Pharmacovigilance*, No 22, May 1988, 1-2.
- Dystonia and withdrawal symptoms with paroxetine (Seroxat). *Current Problems in Pharmacovigilance* 1993, February, 19, 1.
- Views on the Yellow Card scheme, July 1995, 21, 8.
- Adverse Drug Reactions Online Information Tracking (ADROIT) Drug Analysis Prints, 1997-2002.
- Medicines Control Agency, Suspected adverse drug reaction (ADR) reporting and the Yellow Card scheme: Guidance Notes, October 2002.
- Cushny A.R., *A Textbook of Pharmacology and Therapeutics*, 10th edition, London: Churchill, 1928.
- Dahl M.L., Olhager E., Ahlner J., Paroxetine withdrawal syndrome in a neonate (letter), *Br J Psychiatry*, 1997, Oct, 171, 391-2.
- Dallal A., Chouinard G., Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine (letter), *J Clin Psychopharmacol*, 1998, August, 18:4, 343-344.
- D'Arcy P.F., Griffin J.P. (eds), *Iatrogenic Diseases* (3rd edition), Oxford, OUP, 1986.
- Davidoff F., News from the International Committee of Medical Journal Editors, *Ann Intern Med*, 2000;133: 229-231.
- Sponsorship, authorship, and accountability, *Lancet*, 15 September 2001, 358, 854-856.
- Debatista C., Schatzberg A.F., Physical symptoms associated with paroxetine withdrawal (letter). *Am J Psychiatry* 1995 Aug, 152 (8), 1235-4.
- De Buck R., Clinical experience with lorazepam in the treatment of neurotic patients; *Curr Med Res Opin*, 1973, 1, 5, 291-295.

- Delgado P.L., Price L.H., Heniger G.R., Charney D.S., Neurochemistry, in Paykel E.S. (ed.), *Handbook of Affective Disorders*, 2nd Edition, London: Churchill Livingstone, 1992.
- Demyttenaere K., Haddad P., Compliance with antidepressant therapy and antidepressant discontinuation symptoms, *Acta Psychiatr Scand* 2000, 101 (Suppl 403), 50-56. ('Proceedings of a consensus meeting ... sponsored by Eli Lilly & Company').
- Department of Health (Statistics Division, Branch SD1E). *Prescription Cost Analysis* England 1996. London: Department of Health, 1989 - 2003.
- Department of Health, Death rates for suicide and undetermined injury chart, viewed in July 1997 at: [http://www.open.gov.uk/doh/NHS96\\_96/chart04.htm](http://www.open.gov.uk/doh/NHS96_96/chart04.htm)
- De Quincey T., *Confessions of an opium eater*, (1821), London: Walter Scott, 1886.
- Demer D.E., Singleton P.D., Macleod A., Wait S., Taylor M., Ridgwell J., The Informed Patient: Study Report, Cambridge, Judge Institute of Management, March 2003.
- Devanand D.P., Kim M.K., Nobler M.S., Fluoxetine discontinuation in elderly dysthymic patients, *Am. J. Geriatric Psychiatry*, Winter 1997, 5 (1), 83-87.
- De Wilde J., Spiers R., Mertens C., Bartholomé F., Schotte G., Leyman S., A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. *Acta Psychiatr Scand*, 1993, 87, 141-145.
- Diler R.S., Tamam L., Avci A., Withdrawal symptoms associated with paroxetine discontinuation in a nine-year-old boy, *J Clin Psychopharmacol* 2000 Oct; 20 (5): 586-7.
- Dilsaver S. C., Greden J.F., Antidepressant withdrawal phenomena, *Biological Psychiatry*, 1984, 19, 2, 237-256.
- Dilsaver S.C., Antidepressant withdrawal syndromes: phenomenology and pathophysiology, *Acta Psychiatr. Scand.*, 1989, 79, 113-117.
- Withdrawal phenomena associated with antidepressant and antipsychotic agents, *Drug Safety*, 1994, 10 (2), 103-114.
- See also: M. Lejoyeux
- DOH - Department of Health, *Science and Innovation Strategy*, September 2001.
- Dominguez R.A., Goodnick P.J., Adverse events after the abrupt discontinuation of paroxetine. *Pharmacotherapy*, 1995 Nov-Dec, 15 (6), 778-80.
- Donoghue J.M., Tylee A., The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK. *Brit J Psychiatry* 1996, 168, 164-168.
- Donoghue J., Haddad P., Pharmacists lack knowledge of antidepressant discontinuation symptoms [letter], *J Clin Psychiatry* 1999 Feb, 60:2, 124-5.
- Donovan S., Clayton A., Becharry M., Jones S., Kirk C., Waters K., Gardner D., Faulding J., Madeley R., Deliberate self-harm and antidepressant drugs, investigation of a possible link, *Br. J Psychiatry*, 2000, 177, 551-556.
- Doyle C., The cloud over 'bottled sunshine', *Daily Telegraph*, 1 March 1994, 17.
- Drill V.A. (ed.), *Pharmacology in Medicine*, 2nd edition, New York: McGraw Hill, 1958.
- DSRU (Anon), Fluoxetine, PEM Report No. 5, Southampton, Drug Safety Research Unit, 1993.
- DTB (Anon), Some problems with benzodiazepines, *Drug & Therapeutics Bulletin*, 1985, 25 March, 26, 11-12.
- Problems when withdrawing antidepressives, 1986, 21 April, 24, 29-30.
- Fluvoxamine (Faverin): Another antidepressive drug, 1988, 26, 11-12.
- Bupropion to aid smoking cessation, 2000 October, 38 (10), 73-75.
- Fluoxetine, suicide and aggression. 1992, 20 Jan, 30 (2), 5-6.
- Withdrawing patients from antidepressants, July 1999, 37 (7), 49-52.

- Bupropion to aid smoking cessation, 2000 October, 38 (10), 73-75. See also the attached, *Treatment Notes*, Medicines to help you stop smoking, Consumers' Association, December 2000.
- What to do about medically unexplained symptoms, January 2001, 39(1), 5-8.
- Dukes M.N.G., The Van der Kroef Syndrome, Side Effects of Drugs Essay 1990 (Amsterdam: Elsevier, 1990).
- Duphar Laboratories Ltd. (now Solvay Healthcare), Faverin (fluvoxamine) advertisement, *GP*, 1987, Aug 21, 9.
- Edwards G.A., Hodgson R. et al., Nomenclature and classification of drug- and alcohol-related problems: a WHO memorandum, *Bulletin of the WHO*, 1981, 59, 2, 1981: 225-242.
- Egberts T.C.G., Smulders M., de Koning F.H.P., Meyboom R.H.B., Leufkens H.G.M., Can adverse reactions be detected earlier? A comparison of reports by patients and professionals, *Brit Med J.*, 1996, 313, 530-531.
- Einarson A., Selby P., Koren G., Abrupt discontinuation of psychotropic drugs in pregnancy: fear of teratogenic risk and impact of counselling, *J. Psychiatry Neurosci* 2001 January, 26 (1), 44-48.
- Einbinder E., Fluoxetine withdrawal? *Am J Psychiatry* 1995 Aug, 152 (8), 1235.
- Elfenbein D. (ed.), *Living with Prozac and Other Selective Serotonin Reuptake Inhibitors*, San Francisco: Harper Collins, 1995.
- Elgie R., Direct to Consumer Advertising - A matter for debate, *Clinical Journal*, European Union of General Practitioners, 2002, 60-61.
- Ellen E.F., Visits from pharmaceutical reps, *Psychiatric Times*, January 2001, 18(1).
- C. Elliott, Pursued by happiness and beaten senseless: Prozac and the American Dream, *Hastings Center Report*, 2000, 30 No 2, 7-12.
- Elling M.E., Fogle H.J. et al., Making more of pharma's sales force. *The McKinsey Quarterly*, No. 3, 2002.
- Elliott C., Is ugliness a disease? *Guardian*, 26 August 2003.
- Ellis S.J., Matthews C., Weatherby S.J.M., Informed consent is flawed, *Lancet*, 2001 January 13, 357, 149-150.
- Ellison J.M., SSRI withdrawal buzz (letter), *J Clin Psychiatry*, 1994, 55, 544-545.
- EMEA - European Medicines Evaluation Agency, Public Statement on Selective Serotonin Uptake Inhibitors (SSRIs) and Dependency/Withdrawal Reactions, Position paper, EMEA/CPMP/2775/99, London, April 2000.
- EMEA, CPMP Position Paper on Possible Pre-Clinical Studies to Investigate Addiction and Dependence/Withdrawal Related to the Use of SSRIs. London: CPMP/2278/00, December 2000.
- EMEA, Summary report of the heads of agencies ad hoc working group: Establishing a European risk management strategy, <http://heads.medagencies.org/summary.pdf> January 2003.
- Entsuah A.R., Rudolph R.L., Hackett D., Miska S., Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates, *International Clinical Psychopharmacology*, 1996, 11, 137-145.
- Epelde F., Pla R., Aguilar M., Crisis comicial tras supresion brusca del tratamiento con fluoxetine; Letter: in Spanish, re: Seizures crisis following sudden withdrawal of fluoxetine, *Med Clin (Barc)* 1999 Oct 16; 113(12): 479.
- Era News, EC to reconsider advertising rules, November 1998.

- European Parliament, *Analysis of Issues and Trends in the EU Pharmaceuticals Sector*, Environment, Public Health and Consumer Protection Series E-1, External Study (Belcher P.J., Chambers B.R. (eds), The European Parliament, Directorate General for Research, March 1994.
- Evans J.G., Jarvis E.H., Nitrazepam and the elderly, *Brit Med J*, 1972 November 25, 487.
- Fagan M., Withdrawal syndrome after the use of serotonin reuptake inhibitors (in Norwegian) *Tidsskr Nor Laegeforen*, 2000 Mar 20; 120 (8): 913-4.
- Farah A., Lauer T.E., Possible venlafaxine withdrawal syndrome. *Am J Psychiatry* 1996 Apr, 153 (4), 576.
- Fava G.A., Do antidepressant and anti-anxiety drugs increase chronicity in affective disorders? *Psychother Psychosom*, 1994, 61, 125-131.
- Holding On: Depression, sensitisation by antidepressant drugs, and the Prodigious Experts, *Ibid*, 1995, 64, 57-61.
- Fava G.A., Grandi S., Withdrawal syndromes after paroxetine and sertraline discontinuation (letter). *J Clin Psychopharmacol* 1995 Oct, 15 (5), 374-5.
- Fava G.A., Tomba E., The use of antidepressant drugs: some reasons for concern, *Int J of Risk and Safety in Medicine*, 1998, 11, 271-274.
- Fava G.A., Can long-term treatment with antidepressant drugs worsen the course of depression? *Clin Psychiatry*, 2003 February, 64, 2, 123-133.
- Fava M., Rappe S.M., Pava J.A. et al., Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose, *J. Clin. Psychiatry*, 1995, 56, 52-55.
- with Mulroy R., Alpert J., Nierenberg A.A., Rosenbaum J.F., Emergence of adverse effects following discontinuation of treatment with extended-release venlafaxine, *Am J Psychiatry*, December 1997, 154 (12), 1760-1762.
- Favaro A., Friederici S., Santonastaso P., Predictors of sertraline discontinuation syndrome in anorexia nervosa, *J Clin Psychopharmacol*, 21(5), 2001 October, 533-535.
- FDA, *Fluoxetine hydrochloride, Summary Basis of Approval*, NDA 18-936, Rockville Md., US Food & Drug Administration, 3 October 1988.
- Letter to Eli Lilly & Co, 16 November 2000. See <http://www.fda.gov/cder/warn/nov2000/dd9523.pdf>
- *MedWatch Form 3500*, See: <http://www.fda.gov/medwatch/report/consumer/instruct.htm> — June 2003
- Fernando A.T., Schwader P., A case of citalopram withdrawal, *J. Clin Psychopharmacol*, 2000 October, 20 (5), 581-582.
- Ferrier I.N., Treatment of major depression: Is improvement enough? *J. Clin. Psychiatry*, 1999, 60, Suppl. 6, 10-14.
- Ferriman A., Pep-up drug deaths. *The Observer*, 5 June 1988.
- Fieve R.R., *Prozac*, London: Thorsons, 1994.
- Flanagin A., Carey L.A., et al., Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals, *JAMA*, 1998 July 15, 280 (3), 222-224.
- Fossati R., Confalonieri C., Apolone G., Cavuto S., Garattini S., Does a drug do better when it is new? *Ann Oncol*, 2002 Mar; 13 (3): 470-473.
- Freeman H.L., Listening to Prozac (letter), *Nature* 1994 May 19, 369, 178.
- Freudenheim M., Psychiatric drugs are now promoted directly to patients, *The New York Times*, 17 February 1998, A1-D3.
- Friedman E.H., Neurobiology of behavioural changes after prenatal exposure to paroxetine (Paxil), *Am J Obstet Gynecol* 2000 August, 183 (2), 518-519.

- Frost L., Lal S., Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors (letter). *Am J Psychiatry* 1995 May, 152 (5), 810.
- Fullerton A.G., Boardman R.H., Side effects of Tofranil, *Lancet*, 6 June 1959, 1209.
- Galbally R., (Chair) (2000): *Review of Drugs, Poisons and Controlled Substances Legislation*, draft final report. See <http://www.health.gov.au/tga/docs/html/revdp.htm>.
- Gambardella A., Orsenigo L., Pammolli F., Global competitiveness in pharmaceuticals, A European perspective, Report prepared for the Directorate-General Enterprise of the European Commission (2000), available at <http://pharmacos.eudra.org/F3/gio/p3.htm>
- GAO — General Accounting Office, Report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Operations, House of Representatives, *FDA Drug Review — Postapproval drug risks 1976-95*, Report No GAO/PEMD-90-15, Washington DC: GAO, 1990.
- Garattini S., The role of independent science in psychopharmacology, interview with Healy D. in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 142.
- George J., Big Pharma kills doc giveaways, *Philadelphia Business Journal*, 28 June 2002.
- Gerola O. et al., Antidepressant therapy in pregnancy: a review from the literature and report of a suspected paroxetine withdrawal syndrome in a newborn. *Rivista Italiana di Pediatria*, 1999, 25, 216-218.
- Gerth G., Stohlberg S.G., Medicine merchants: Birth of a blockbuster, *New York Times*, 23 April 2000.
- Drug industry has ties to groups with many different voices, *New York Times*, 5 Oct 2000.
- Giakas W.J., Davis J.M., Intractable withdrawal from venlafaxine treated with fluoxetine, *Psychiatric Annals*, February 1997, 27 (2), 85-86 and 92.
- Glass A., European Commission may reform drug advertising legislation, *Lancet*, 358, 28 July 2001, 306.
- Glenmullen J., *Prozac Backlash* — overcoming the dangers of Prozac, Zoloft, Paxil, and other antidepressants with safe, effective alternatives, (New York: Simon & Schuster, 2000).
- Gluck M.E., *Federal policies affecting the cost and availability of new pharmaceuticals*, The Henry J. Kaiser Family Foundation, July 2002, p. 35.
- Goldberg J.F., Kocsis J.H., Relapse during SSRI treatment for depression, *Medscape Psychiatry & Mental Health Journal*, 1996, 1, 5. [www.medscape.com/viewarticle/431525](http://www.medscape.com/viewarticle/431525)
- Goldberg R., Cloning Kessler — a bad choice for the FDA, *National Review Online*, 11 January 2002.
- Goldberg R.J., Diagnostic dilemmas presented by patients with anxiety and depression. *Am J Medicine*, 1995 Mar. 98, 278-284.
- Goldstein T.R., Frye M.A., Denikoff K.D., Smith-Jackson E., Leverich G.S., Bryan A.L., Ali S.O., Post R. M., Antidepressants and discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder, *J. Clin Psychiatry*, August 1999, 60 (8), 563-567.
- Goodman L.S., Gilman A. (eds), *The Pharmacological Basis of Therapeutics*, New York: Macmillan, 1941.
- Gore S.M., Jones G., Thompson S.G., The *Lancet's* statistical review process: areas for improvement by authors, *Lancet*, July 11 1992, 340, 100-102.

- Gram L.F., (in Danish) Seponeringssymptomer ved anvelndelse af selektive serotoningen-optagelseshæmmere (SSRI), *Ugeskr Læger*, 1998, 7 Dec, 160 (50), 7291-7293.
- Grant R., The Prozac generation, *The Independent on Sunday*, 30 Jan 1994, 12-16.
- Green B., Persistent adverse neurological effects following SSRI discontinuation, Psychiatry On-Line, accessed January 2000 on <http://www.priory.com/psych/panes.htm>
- Greenberg R.P., Greenberg D., Bornstein R.F., Fisher S., A meta-analysis of antidepressant outcome under "blinder" conditions, *J. Consulting & Clinical Psychology*, 1992, 60 (5), 664-669.
- Greenberg R.P., Fisher S., Examining antidepressant effectiveness: findings, ambiguities and some vexing puzzles, in R.P. Greenberg & S. Fisher (eds), *The Limits of Biological Treatments for Psychological Distress - Comparisons with Psychotherapy and Placebo*, [Hillsdale, New Jersey: Lawrence Erlbaum Associates, 1989], 1-37.
- Griffin J.P., Is better feedback a major stimulus to spontaneous adverse reaction monitoring? *Lancet*, 1984, November 10, 1098
- Groppe M., Lilly beefs up lobbying staff to flex political muscle, *Indianapolis Star*, 21 July 2002.
- Gurwitz J.H., Field T.S., Avorn J., et al., Incidence and preventability of adverse drug events in nursing homes, *Am J Med*, 2000, 109 (2), 87-94.
- Haddad H. cited in McGregor G., Ban on Ads to Stay: McLellan, *The Ottawa Citizen*, 23 March 2002.
- Haddad P., Lejoyeux M., Young A., Antidepressant discontinuation reactions are preventable and simple to treat, *Brit Med J*, 11 April 1998, 316, 1105-1106.
- Haddad P., Anderson I., Antidepressants aren't addictive: clinicians have depended on them for years, (comment on Healy and Tranter, 1999) *J Psychopharmacol.*, 1999, 13 (3), 291-298.
- Haddad P., Do antidepressants have any potential to cause addiction? *J. Psychopharmacol.*, 1999, 13 (3), 300-307.
- Haddad P., Qureshi M., Misdiagnosis of antidepressant discontinuation symptoms, *Acta Psychiatr Scand* 2000 Dec, 102 (6), 466-468.
- Haddad P., Antidepressant discontinuation syndromes, *Drug Safety*, 2001, 24 (3), 183-197.
- Haddad P., The SSRI discontinuation syndrome, *J. Psychopharmacology*, 1998, 12 (3), 305-313.
- Hale A.S., Anxiety, *Brit. Med. J.*, 1997, 28 June, 314, 1886-1889.
- Halle H., Del Medico V.J., Dilsaver S.C., Symptoms of major depression: acute effect of withdrawing antidepressants, *Acta Psychiatr. Scand.*, 1991, 83, 238-239.
- Hallstrom C., Benzodiazepine dependence: who is responsible? *J. Forensic Psychiatry*, 1991, 2 (1), 5-7.
- Hamburger T., Drug industry moves to boost image before vote, *Wall Street Journal*, 16 September 2002, A6.
- Hamilton, M., Development of a rating scale for primary depressive illness. *Brit J Soc Clin Psychol* 1967, 6, 278-296.
- Hamner M. & Huber M.: Discontinuation of antidepressant medications prior to ECT, *Convulsive Ther*, 1996, 12, 125-126.
- Hampton J.R., Clinical freedom, *Brit Med J*, 1983 October 29, 287, 1237-1238.
- Hare E.H., Dominian J., Sharpe L., Phenelzine and dexamphetamine in depressive illness, *Brit. Med. J.*, 6 Jan, 1992, 9-12.
- Hare D., 'My vote? I would like to punish Blair', *Daily Telegraph*, 17 May 2001.
- Harris G., Drug firms stymied in the lab, become marketing machines, *Wall Street Journal*, 6 July 2000.
- Harry T.V.A., (Wyeth UK), Oxazepam (Serenid D) dependence, *Brit. J. Psychiatry*, 1972, 121, 235-236.
- Hawley C.J., James D.V., Birkett P.L., Baldwin D.S., M.J. de-Ruiter, R.G. Priest, Suicidal ideation as a presenting complaint. Associated diagnoses and characteristics in a casualty population, *Br J Psychiatry* 1991 Aug, 159, 232-8.
- Hawkins B., Paxil is forever, *City Pages*, 23, 1141, 16 October 2002.
- Healy D., The structure of psychopharmacological revolutions. *Psychiatr. Dev.* 1987, 5, 349-376.
- The psychopharmacological era: notes towards a history. *J Psychopharmacol* 1990, 4 (3), 152-167.
- The marketing of 5-Hydroxytryptamine: Depression or anxiety? *Br J Psychiatry* 1991, 158, 737-742.
- *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996.
- *The Antidepressant Era*, Cambridge, Mass., Harvard University Press, 1998.
- *The Psychopharmacologists II*, London: Chapman & Hall (Altman), 1998.
- Commentary on Moncrieff J. et al., Meta-analysis of trials comparing antidepressants with active placebos, *Brit J Psychiatry*, 1998, 172, 232-234.
- with Tranter R.: Pharmacological stress diathesis syndromes, *J Psychopharmacol.*, 1999, 13 (3), 287-290. And: In the shadow of the benzodiazepines (Responses to commentaries on the above paper), *ibid*, p. 299.
- Good science or good business? *Hastings Center Report*, 2000, 30 No 2, 19-22.
- *The Psychopharmacologists III*, London: Arnold (with OUP), 2000.
- Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors, *Psychotherapy and Psychosomatics*, 2003; 72, 71-79.
- *Let them eat Prozac*, Toronto: Lorimer, 2003.
- Heeley E., Riley J., Layton D., Wilton L.V., Shakir S.A.W., Prescription-event monitoring and reporting of adverse drug reactions, *Lancet*, 1 December 2001, 358, 1872-1873.
- Heerdin E.R., Urquhart J., Hubert G., Leufkens H.G., Changes in prescribed drug doses after market introduction, *Pharmacoepidemiol Drug Saf.* 2002 Sep; 11 (6):447-53.
- Helling-Borda M., Memories of the First Expert Committee Meeting and celebrating 25 years later, *Essential Drugs Monitor*, 2003, 32, 14-15.
- Hicks C., The truth about Nature's Prozac, *Independent*, 8 July 1997, tabloid section, 9.
- Herxheimer A., How much drug in the tablet? *Lancet*, 1991, Feb 9, 337, 346-348.
- Hindmarch I., Kimber S., Cockle S.M., Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance, *Int Clin Psychopharmacol* 2000 Nov; 15 (6): 305-18.
- Hirose S., Restlessness related to SSRI withdrawal, *Psychiatry and Clinical Neurosciences*, 2001, 55, 79-80.
- Hirschfeld R.M.A., Keller M.B., Panico S., et al., The National Depressive and Manic-Depressive Association Consensus Statement on the Undertreatment of Depression. *JAMA*, 1997, 277 (4), 333-340.
- Hollister L. E., Motzenbecker F.P., Degan R.O., Withdrawal reactions from chlor-diazepoxide ('Librium'), *Psychopharmacologia*, 1961, 2, 63-68.
- et al., Diazepam in newly admitted schizophrenics, *Dis Nerv Sys*, 1963 December, 746-750.
- Clinical use of psychotherapeutic drugs, *Drugs*, 1972, 4, 321-360.

- The prudent use of anti-anxiety drugs, *Rational Drug Therapy*, 1972 March, 6 (3), 1-6.
- (Chairman, proceedings of a roundtable discussion on diazepam held in Chicago, 20 May, 1976), Valium: a discussion of current issues. *Psychosomatics* 1977, 18 (1), 44-58.
- 'Pharmacological stress diathesis syndromes': commentary, (on Healy and Tranter, 1999) *J Psychopharmacol.* 1999, 13 (3), 293-294.
- Horrobin D.F., *Medical Hubris: A reply to Ivan Illich*, London: Churchill Livingstone, 1978.
- Innovation in the pharmaceutical industry, *J. Roy. Soc. Med.*, July 2000, 93, 341-345.
- Something rotten at the core of science? *Biomednet* (bmj.com), February 2001.
- Horton R., Lotronex and the FDA: a fatal erosion of integrity, *Lancet*, 19 May 2001, 1544-5.
- Huffstutler S.Y., Management of antidepressant withdrawal reactions, *J Am Acad Nurse Pract*, 1998, April, 10:4, 161-165.
- Hunt M.I., *Prescription Drug Costs: Federal Regulation of the Industry*, Report for the Blue Cross and Blue Shield Association, September 2000.
- Hunt L., Mind drug 'no miracle', *Independent on Sunday*, 31 October 1993, 2.
- Hunt P., McKillop T. (co-chairs), Pharmaceutical Industry Competitiveness Task Force, Final report, March 2001. Available at <http://www.doh.gov.uk/pictf/index.htm>
- Hunter R.A., The abuse of barbiturates and other sedative drugs with special reference to psychiatric patients, *British J Addiction*, 1957, 53, 2, 93-100.
- Hyman S.E., Nestler E.J., Initiation and adaptation: A paradigm for understanding psychotropic drug action. *Am J Psychiatry* 1996 Feb, 153 (2), 151-162.
- Ibister G.K., Dawson A., Whyte I.M., Prior F.H., Clancy C., Smith A.J., Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? *Arch Dis Child Fetal Ed*, 2001, Sept, 85 (2), F147-148.
- Illich I., *Limits to Medicine – Medical Nemesis: the Expropriation of Health*, (London: Marion Boyars, 1976 (originally published in *Ideas in Progress*, January 1975).
- Inman W.H.W., Detection and investigation of drug safety problems, in Gent & Shigamatsu (eds), *Epidemiological issues in reported drug-induced illnesses*. Hamilton, Ontario: McMaster University Library Press, 1976.
- Kubota K., Pearce G., Wilton L., PEM Report Number 6. Paroxetine, *Pharmaco-epidemiology and Drug Safety*, 1993, 2, 393-422.
- *Don't tell the patient*, Los Angeles and Hampshire: Highland Park, 1999.
- Inpharm: [http://www.inpharm.com/External/InpH/1,2272,5-204-0-0-inp\\_free\\_front-o-A,00.html](http://www.inpharm.com/External/InpH/1,2272,5-204-0-0-inp_free_front-o-A,00.html) accessed February 2003.
- Inpharm.com, Africa Pharmaceutical Sector Development, 11 July 2003, Source: World Pharmaceutical Markets.
- IOB – Institute of Medicine: *Sleeping Pills, Insomnia and Medical Practice*, (Washington DC: National Academies Press, 1979).
- *Integrity in Scientific Research: Creating an environment that promotes responsible conduct*, 2002.
- Isbell H., Altschul S., et al., Chronic barbiturate intoxication – An experimental study, *Arch. Neurology & Psychiatry*, 1950 July, 64, 1, 1-28.
- Jackson C.A., Pitkin K., Kington R., (1998), 'Evidence-based decision-making for community health programs.' <http://www.rand.org/publications/MR/MR933/MR933.pdf/>.
- Jacob J., Welcoming or wary? Drug reps increasing, *AMNews*, American Medical Association, 16 April 2001.
- Jacobs D., Cohen D., What is really known about psychological alterations produced by psychiatric drugs? *Int. J. Risk & Safety in Medicine*, 1999, 12, 37-47.

- James O., Camden C., Power of the psychodrug, *Guardian* (Magazine section), 23 November 1993, 14-15.
- Jefferson T., Wager E., Davidoff F., Effects of editorial peer review: a systematic review. *JAMA*. 2002 Jun 5;287(21):2784-6. Review. Also: Measuring the quality of editorial peer review, 2786-90.
- Jeffries M., The mark of Zorro, *Pharmaceutical Marketing*, May 2000, 4-5.
- Jick S.S., Dean A.D., Jick H., Antidepressants and suicide. *Brit Med J* 1995, 310, 215-8.
- John K., Democracy, accountability, and international health: Westminster from a medical perspective, *Lancet*, 2003 September 6, 362, 826-827.
- Johnson H., Bouman W.P., Lawton J., Withdrawal reaction associated with venlafaxine, *Brit. Med. J.*, 19 September 1998, 317, 787.
- Jones E., *Sigmund Freud: Life and Work*, Vol 1, London: Hogarth Press, 1953.
- Jones G., Mann R., Better reporting of adverse drug reactions, *Brit Med J*, 4 April 1987, 901-902.
- Judge R., Parry M.G., Quail D., Jacobson J.G., Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment, *Int. Clin. Psychopharmacol.* 2002, 17, 217-225.
- Kaiser Family Foundation study cited in Agovino T., Drug companies revise guidelines for marketing drugs to doctors, Associated Press, 19 April 2002.
- Kales A., Bixler E.O., Tjiauw-Lin Tan, Scharf M.B., Kales J.D., Chronic hypnotic drug use – ineffectiveness, drug-withdrawal insomnia and dependence, *JAMA*, 1974 February 4, 227 (5), 513-517.
- Manfredi R.L. et al., Rebound insomnia following only brief and intermittent use of rapidly eliminated benzodiazepines, *Clin Pharm Ther*, 1991, 49, 468-476.
- Kaller A., Schlink F.J., *100,000,000 Guinea Pigs*, Dangers in everyday food, drugs and cosmetics, (New York, Vanguard, 1932).
- Karp D.A., *Speaking of Sadness* New York City and Oxford, UK: Oxford University Press, 1996.
- Kasantikul D., Reversible delirium after discontinuation of fluoxetine. *J Med Assoc Thai*, 1995 Jan, 78 (1), 53-54.
- Kaufman M., Since Bush's inauguration, partisan politics and industry demands have delayed appointment, *Washington Post*, 15 July 2002.
- Keller M.B., in discussion of the natural history and heterogeneity of depressive disorders: Implications for rational antidepressant therapy, *J Clin Psychiatry* 1994 Sept., 55, 9 (suppl A), 32-33.
- Keller M.B., Hanks D.L., Anxiety symptom relief in depression treatment outcomes, *J. Clin. Psychiatry*, 1995, 56 Suppl. 6, 30-36.
- Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J., Markowitz J.C., Nemeroff C.B., Russell J.M., Thase M.E., Trivedi M.H., Zajecka J., A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *N Engl J Med*. 2000 May 18; 342 (20): 1462-70.
- Keller M.B., Ryan N.D., Strober M., Klein R.G., et al., Efficacy of paroxetine in the treatment of adolescent major depression: A randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2001; 40 (7): 762-72.
- Kennedy P., Has the US lost its way? *Observer*, 3 March 2002.
- Kent L.S.W., Laidlaw J.D.D., Suspected congenital sertraline dependence *Brit J Psychiatry* 1995 Sep, 167 (3), 412-3.



- Kerr M.P., Antidepressant prescribing: a comparison between general practitioners and psychiatrists. *Brit J Gen Pract* 1994, 44, 275-276.
- Keuthen N.J., Cyr P., Ricciardi J.A., et al., Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. *J Clin Psychopharmacol* 1994 Jun, 14 (3), 206-7.
- Kirsch I., Sapirstein G., Listening to Prozac but Hearing Placebo; A Meta-Analysis of Antidepressant Medication, *Prevention & Treatment*, Vol 1, Article 0002a, posted June 26, 1998 at <http://journals.apa.org/prevention/volume1/pre0010002a.html>
- Kirsch I., Moore T.J., Scoboria A., Nicholls S.S., The Emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration, *Prevention & Treatment*, Volume 5, Article 23, Posted 15 July 2002, at <http://journals.apa.org/prevention/volume5/pre0050023a.html>
- Kirsch M., Hard habit to break, *The Observer Magazine*, 3 February 2002, 46.
- Kissinger H., Opening address to the World Food Conference, UN Food & Agriculture Organization, Rome, November 1974.
- Kjaergard L.L., Als-Nielsen B., Association between competing interests and authors' conclusions: epidemiological study of randomised trials published in the *BMJ*, *Brit Med J*, 3 August 2002 325, 249-252.
- Kline N.S., The practical management of depression. *JAMA*, 1964 Nov 23, 190 (8), 122-130.
- Koerner B.I., Disorders made to order, *Mother Jones*, 1 August 2002.
- Koopowitz L.F., Berk M., Paroxetine induced withdrawal effects, *Human Psychopharmacol.*, 1995, 10, 147-148.
- Kotlyar M., Golding M., Brewer E.R., Carson S.W., Possible Nefazodone withdrawal syndrome (letter), *Am J Psychiatry*, July 1999, 156 (7), 1117.
- Kramer J.C., Klein D.F., Fink M., Withdrawal symptoms following discontinuation of imipramine therapy, *Am. J Psychiatry*, 1961, 118, 549-550.
- Kramer P.D., *Listening to Prozac*. New York: Viking, 1993.
- The valorization of sadness: Alienation and the melancholic temperament, *Hastings Center Report*, 2000, 30 No 2, 13-18.
- Kreider M.S., Bushnell W.D., Oakes R. et al., A double-blind randomised study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period, *J. Clin Psychiatry*, 1995, 56, 142-145.
- Krimsky S., Conflict of interest and cost-effectiveness analysis, *JAMA*, 1999 October 20, 282, 15, 1474-1475.
- Conflict of interest policies in science and medical journals: Editorial Practices and Author Disclosures, *Science and Engineering Ethics*, 2001, 7, 205-218.
- Lacey R., Woodward S., That's Lifel survey on tranquillisers, London, British Broadcasting Corporation in association with MIND (National Association of Mental Health), 1985.
- Lader M., Benzodiazepine withdrawal states. In M.R. Trimble (ed.), *Benzodiazepines Divided* (Chichester: John Wiley & Son, 1983).
- Benzodiazepine dependence syndromes and syndromes of withdrawal. In Hallstrom C. (ed.), *Benzodiazepine Dependence* (Oxford University Press, 1993).
- Withdrawal from antidepressants (Unpublished Opinion), November 1997.
- Lancet*, Editorial, 11 February 1865, 153-154.
- Editorial, 1 January 1870, 15.
- Editorial, 1889, ii, 1047.
- Editorial, 1954, ii, 75.

- Annotation, 21 May 1955, 1065.
- Editorial: Just how tainted has medicine become? 2002 April 6, 359, 9313, 1167.
- Landry P., Roy L., Withdrawal hypomania associated with paroxetine, *J. Clin. Psychopharmacol.*, 17, 1, February 1997, 60-61.
- Lane R.M., Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors, *J. Serotonin Res.*, 1996, 3, 75-83.
- La Revue Prescrire*, A look back at 2000: overabundance and deregulation. *Prescrire International* 2001, 10: 52-4.
- Larkin M., Whose article is it anyway? *Lancet*, 2002, 354, 9173, 136.
- Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., Bor D.H., Timing of new black box warnings and withdrawals for prescription medications. *JAMA*, 2002 May 1; 287(17): 2215-2220. See also Wolfe S.M., Drugs banned since the time of the JAMA study, at [http://www.citizen.org/publications/print\\_release.cfm?ID=7171](http://www.citizen.org/publications/print_release.cfm?ID=7171)
- Lauber C., Nefazodone withdrawal symptoms, *Can J Psychiatry*, April 1999, 44 (3), 285-286.
- Lazarou J., Pomeranz B.H., Corey P.N., Incidence of adverse drug reactions in hospitalized patients – A meta-analysis of prospective studies, *JAMA*, 1998;279: 1200-1205.
- Lazowick A.L., Levin G.M., Potential withdrawal syndrome associated with SSRI discontinuation. *Ann Pharmacother* 1995 Dec, 29 (12), 1284-85.
- Lehmann H., Psychopharmacotherapy, interview with D. Healy in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 178-179, 182, 185.
- Leiter F.L., Nierenberg S.A., Sanders K.M., Stern T.A., Discontinuation reactions following sertraline. *Biol Psychiatry* 1995 Nov 15, 38 (10), 694-5.
- Lejoyeux M., Ades J., Mourad I., Solomon J., Dilsaver S., Antidepressant withdrawal syndrome – recognition, prevention and management, *CNS Drugs*, 1996, April; 5, 4, 278-292.
- Lewis A. J., *J. Ment. Sci.*, 1934, 80, 277.
- Leyburn P., A critical look at antidepressant drug trials. *Lancet* 1967 25 Nov, 1135-1138.
- Eli Lilly & Co (Dista Products), First line for all nine ... symptoms of depression, *J. Clin. Psychopharmacol.*, 1993, 13, 5, advertisement facing p. 303.
- Lindqvist M., *Seeing and Observing in International Pharmacovigilance*, Uppsala, Sweden: Uppsala Monitoring Centre, 2003.
- Lonngren T. (Director, EMEA) quoted in Anon, Dry pipelines undermining EMEA, *Pharmafocus*, 30 December 2002.
- Louie A.K., Lewis T.B., Lannon R.A., Use of low dose fluoxetine in major depression and panic disorder, *J Clin. Psychiatry* 1993, Nov, 54 (11), 435-438.
- Louie A.K., Lannon R.A., Ajari L.J., Withdrawal reaction after sertraline discontinuation (letter). *Am J Psychiatry* 1994 Mar, 151 (3), 450-1.
- Louie A.K., Lannon R.A., Kirsch M.A., Lewis T.B., Venlafaxine withdrawal reactions (letter). *Am J Psychiatry* 1996 Dec, 153 (12), 1652.
- Lu L., Su W.J., Yue W., Ge X., Su F., Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. *Life Sci*, 2001 May, 69, 1, 37-46.
- Luckhaus C., Jacob C., Venlafaxine withdrawal syndrome not prevented by maprotiline, but resolved by sertraline (letter), *Int J Neuropsychopharmacology*, 2001, 4, 43-44.
- Luckhaus C., Müller W.E., (in German) Withdrawal symptoms after prolonged intake of specific serotonin reuptake inhibitors, *Psychopharmacotherapie*, 2000, 7, 57-62.

- Lumley C.E., Walker S.R., Hall G.C., Staunton N., Grob P.R., The under-reporting of adverse drug reactions seen in General Practice, *Pharmaceutical Medicine*, 1986, 1, 205-212.
- Lurie P., Statement of Peter Lurie, M.D., MPH before National Academy of Sciences' Committee on Clinical Research Involving Children (HRC publication No. 1668). Washington DC: Health Research Group, 2002.
- Lynch T., *Beyond Prozac: Healing Mental Suffering Without Drugs*, Dublin, Marino Books, 2001.
- Lynn M., *The Billion Dollar Battle – Merck v Glaxo*, Heinemann, London, 1991, 195.
- Macbeth R., Rajagopalan M., Venlafaxine withdrawal syndrome, *Aust NZ J Med*, 1998, 28, 218.
- Macdonald L., Discontinuation symptoms and SSRIs, *CMAJ*, 1998, Oct 6, 159(7), 846-847, and (in French) 850-852.
- Mackay F.J., Dunn N.R., Wilton L.V., Pearce G.L., Freemantle S.N., Mann R.D., A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies, *Pharmacoepidemiology and Drug Safety*, 1997, 6, 235-246.
- Mahendran R., Chan A., Selective Serotonin Reuptake Inhibitor discontinuation symptoms, *Ann. Acad. Med. Singapore*, 1999, July, 28, 596-599.
- Maixner S.M., Greden J.F., Extended antidepressant maintenance and discontinuation syndromes, *Depress Anxiety* 1998, 8, Suppl 1, 43-53.
- Maletzky B.M., Klotter J., Addiction to Diazepam, *Int. J. of the Addictions*, 1976, 11 (1), 95-115.
- Malitz S., Kanzler M., Are antidepressants better than placebo? *Am. J. Psychiatry*, 1971, 127, 1605.
- Mallya G., White K., Gunderson C., Is there a serotonergic withdrawal syndrome? *Biol Psychiatry* 1993 Jun 1-15, 33 (11-12), 851-2.
- Manolis D.C., The perils of Prozac, *Minnesota Medicine* 1995 Jan, 78, 19-23.
- Mareth T.R., Brown T.M., SSRI withdrawal (letter), *J Clin Psychiatry* 1996 Jul, 57 (7), 310.
- Marinker M. in Parish P.A., Williams W.M., Elmes P.C. (eds), *The Medical Use of Psychotropic Drugs*, a report of a symposium sponsored by the Department of Health and Social Security, held at University College, Swansea, 1-2 July 1972.
- Markowitz J.S., Selective serotonin reuptake inhibitor discontinuation with BCT and withdrawal symptoms (letter), *J ECT*, 1998, March, 14:1, 55.
- Nefazodone withdrawal symptoms, *Can J Psychiatry*, April 1999, 44 (3), 286-287. Letter, Comment on Benazzi F., March 1998.
- Marks J., *The Benzodiazepines – Use, Overuse, Misuse, Abuse*. Lancaster UK: MTP Press, 1978.
- The benzodiazepines – for good or evil, *Neuropsychobiology* 1983, 10, 115-126.
- Mathew T. (Chair, ADRAC), SSRIs and withdrawal syndrome, *Australian Adverse Drug Reactions Bulletin*, 15, 1, November 1996, 2.
- Mathew T., SSRIs and neonatal disorders: Withdrawal reactions, Breast milk transfer, *AADRB*, 16, 4, November 1997, 14.
- Mathews A.W., FDA chief targets Europe's controls on drug price, *Wall Street Journal*, 25 September 2003.
- Maudsley H., *The Pathology of Mind*, London: Macmillan, 1895.
- MCA – Medicines Control Agency, Quinquennial review and prior options study, May 1999.

- McBride M. (Honorary Secretary of Council, Royal College of General Practitioners), Unpublished correspondence, 18 May 1992.
- McCallum R.D., Kell G.C., Phelps A., Deposition, 4 September 2002, in Re Paxil litigation, CV-01-07937 MRP (CWx)
- McKeown T., Lowe C.R., *An Introduction to Social Medicine*, Oxford, Blackwell, 1974.
- *The Role of Medicine: Dream, Mirage, or Nemesis?* Princeton, NJ, Princeton University Press: 1979.
- *The origins of human disease*, Oxford, Blackwell, 1988.
- McNair D.M., Anti-anxiety drugs and human performance, *Arch Gen Psychiatry*, 1983 November, 29, 611-617.
- Medawar C., See also www.socialaudit.org.uk (1998-2003)
- *Power and Dependence: Social Audit on the safety of medicines*. London: Social Audit, 1992. (P&D is the prime source for Chapters one and two in this book)
- Through the doors of deception? *Nature*, 24 March 1994, 368, 369-370.
- Secrecy and medicines. *Int J Risk & Safety in Medicine* 1996, 9 133-141.
- The Antidepressant Web – Marketing depression and making medicines work, *Int. J. Risk & Safety in Medicine*, 10, 1997, 75-126.
- Herxheimer A., Bell A., Jofre S., Paroxetine, *Panorama* and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance, *Int. J. Risk & Safety in Medicine* 2002; 15, 161-169.
- Herxheimer A., Risk of suicidality and dependence with Paroxetine: Comparing Yellow Card reports of suspected adverse drug reactions with reports from users, *Int. J. Risk & Safety in Medicine*, 2003, 16, 3-17.
- Medawar J., Pyke D., *Hitler's Gift – Scientists who fled Nazi Germany*, (London: Richard Cohen, 2000)
- Medawar P.B., *Advice to a Young Scientist*, (New York: Harper Row, 1979).
- Médecins Sans Frontières: see MSF.
- Medical Letter (Anon), Librium, 13 May 1960, 2, 10, 37-38.
- Drugs for psychiatric disorders, *Med. Lett.*, 11 April 1997, 39, 998, 33-40.
- Meek C., Fraud & misconduct in medical research, *Health Which?* December 2001, 21-24.
- Questioning antidepressants, *Health Which?* February 2002, 22-25.
- Melrose D., *Bitter Pills*, medicines and the third world poor, Oxford: OXFAM, 1982.
- Menecier P., Menecier-Ossia L., Bern P., Fluoxetine dependence and tolerance. Apropos of a case (English abstract, French text), *Encephale*, 1997, Sept-Oct, 23(5), 400-401.
- Merry J., Biochemistry and drug treatment of depression, *Lancet*, May 27 1972, 1175-1176.
- Mhanna M.J., Bennet J.B., Izatt S.D., Potential fluoxetine chloride (Prozac) toxicity in a newborn, *Pediatrics*, 1997, 100, 158-159.
- Michaels A., Pfizer R&D unable to sustain group growth rate, *Financial Times*, 12 September 2001, 30.
- Michelson D., Fava M., Amsterdam J., Apter J., Lønborg P., Tamura R., Tepner R.G., Interruption of selective serotonin reuptake inhibitor treatment, *Br J Psychiatry*. 2000 Apr; 176:363-8.
- MHRA – Medicines and Healthcare products Regulatory Agency – email to Social Audit, 12 November 2003.
- Milgram S., *Obedience to authority; an experimental view*. New York: Harper & Row, 1974.
- Millar J.S., Consultations owing to adverse drug reactions in a single practice, *Br J Gen Practice*, 2001, 51, 130-131.

- Miller M. C., Symptoms that start when an antidepressant stops, *Harvard Mental Health Letter*, February 2001, 6-7.
- Mintzes B., *Blurring the Boundaries* – new trends in drug promotion, Amsterdam: Health Action International, 1998.
- MLI – MedicoLegal Investigations: <http://www.medicolegal-investigations.com/about1.htm> (accessed November 2003).
- Mohan C.G., Moore J.J., Fluoxetine toxicity in a preterm infant, *J Perinatol* 2000 Oct-Nov, 20 (7), 445-446.
- Moncrieff J., Wessely S., Hardy R., Meta-analysis of trials comparing antidepressants with active placebos, *Brit J Psychiatry*, 1998, 172, 227-231. with Commentary (D. Healy) pp. 232-234.
- Moncrieff J., Review of randomised controlled trials of antidepressants using active placebos [Protocol]. In P. Bech, R. Churchill, D. Gill, P. Hazell, M. Oakley-Browne, M. Trivedi, S. Wessely (eds), *Depression, Anxiety and Neurosis Module of the Cochrane Database of Systematic Reviews*, [updated 1 September 1997]. Available in The Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration; Issue 4. Oxford: Update Software; 1997. Quarterly.
- Are antidepressants overrated? A review of methodological problems in antidepressant trials, *J Nervous & Mental Disease*, 2001, 189(5), 288-295.
  - *Is psychiatry for sale?* an examination of the influence of the pharmaceutical industry on academic and practical psychiatry, Maudsley discussion paper No. 13, London: Institute of Psychiatry, 2003.
- Montgomery S.A., Lambert M.T., Pitfalls in assessing efficacy and side-effects of antidepressants, *Int. J. Clin. Pharm. Res.*, 1989, 9 (2), 95-100.
- Green M., Baldwin D., Montgomery D., Prophylactic treatment of depression: a public health issue, *Neuropsychobiol.*, 1989, 22, 214-219.
  - The efficacy of fluoxetine as an antidepressant in the short and long term, *Int. J. Clin. Psychopharmacol.*, 1989 Jan., 4, Suppl. 1, 113-119.
  - Long-term treatment with SSRIs, *Clin. Neuropharmacol.*, 1992, 15, Suppl 1 Part A, 450A-451A.
  - Introduction (Antidepressants: perspectives in primary and secondary health care) *Postgrad Med J* 1994, 70 Suppl 2, S1.
  - Dunbar G., Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression, *Int. J. Clin. Psychopharmacol.*, 1993, 8, 189-195.
  - Roberts A., Patel A.G., Placebo-controlled efficacy on antidepressants in continuation treatment, *Int. J. Clin. Psychopharmacol.*, 1994 Jan., 9, Suppl. 1, 49-53.
  - Antidepressants in long-term treatment, *Annu. Rev. Med.*, 1994, 45, 447-457.
  - Long-term treatment of depression, *Brit. J. Psychiatry* 1994, 165, Suppl. 26, 31-36.
  - Efficacy in long-term treatment of depression, *J. Clin. Psychiatry*, 1996, 57, Suppl. 2, 24-30.
- Moore T.J., *Deadly Medicine*, New York: Simon & Schuster, 1995.
- Hidden dangers of antidepressants, *The Washingtonian*, December 1997, 68-71 and 140-145.
  - It's what's in your head, *The Washingtonian*, October 1999, 45-48.
- MORI Public Opinion Polls: Attitudes towards Depression: Research study conducted for the 'Defeat Depression' Campaign. London: Royal College of Psychiatrists, Royal College of General Practitioners, January 1992.

- Morrison-Griffiths S., Walley T.J., Park B.K., Breckenridge A.M., Pirmohamed M., Reporting of adverse drug reactions by nurses, *Lancet*, 2003, April 19, 361, 1347-1348.
- Mourad I., Lejoyeux M., Ades J., Evaluation prospective du sevrage des antidépresseurs, *L'Encephale*, 1998, 24, 215-222.
- Mowatt G., Shirran L., et al., Prevalence of honorary and ghost authorship in Cochrane reviews, *JAMA* 2002 Jun 5; 287 (21):2769-71.
- Moynihan R., Celebrity selling, *Brit Med J*, 2002 June 1, 324, 1342 and *Brit Med J*, 2002 August 3, 325, 286.
- Mrela C.K., Mortality Topic 1, Arizona Center for Health Statistics, seen at <http://www.hs.state.az.us/plan/suicid95/topic1.htm> on 7/7/97.
- MSF – Médecins Sans Frontières: *Fatal Imbalance The Crisis in Research and Development for Drugs for Neglected Diseases*, Brussels: MSF International, 9 October 2001.
- Mukamal K.J., Conigrave K.M., Mittleman M.A., et al., Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men, *N Eng J Med*, 2003, January 9, 348 (2), 109-118.
- Munro G., Evidence to the Parliamentary Public Accounts Committee Enquiry: Safety, quality, efficacy: regulating medicines in the UK, HC 505, 5 March 2003, 32.
- Nakielnny J., The fluoxetine and suicide controversy. A review of the evidence. *CNS Drugs* 1994, 2, 252-253.
- NAO – National Audit Office: *Safety, quality, efficacy: regulating medicines in the UK*, Report by the Comptroller and Auditor General, HC 255, Session 2002-2003, 16 January, 2003 (London: The Stationery Office, 2003).
- Nathan R.G., Kinney J.L., Long-term dependence on antidepressants, *Am J Psychiatry*, April 1985, 142 (4), 524.
- National Institute of Mental Health Consensus Study, *Electroconvulsive Therapy*, excerpt published April 1997 at <http://www.schizophrenia.com/ami/meds/ect.html>
- NMDA – The National Depressive and Manic-Depressive Association Consensus Statement on the Under-treatment of Depression, *JAMA*, 1997, 277, 333-340.
- Nemeroff C.B., DeVane C.L., Pollock B.G., Newer antidepressants and the cytochrome P450 system, *Am J Psychiatry*, 1996 March, 153, 3, 311-320.
- N Eng J Med* – *New England Journal of Medicine* (Anon), Drug abuse control amendments of 1965, *N. Eng J Med*, 1965 25 November, 273, 22, 1222-1223.
- New York Times* (Editorial), Ending a patent scam, 22 October 2002.
- NIHCM, *Prescription Drugs and Intellectual Property Protection – Finding the Right Balance between Access and Innovation*, Issue Brief, (Washington DC: National Institute for Health Care Management and Educational Foundation, August 2000).
- *Prescription Drugs and Mass Media Advertising, 2000*, a research report by The National Institute for Health Care Management Research and Educational Foundation, 20 November 2001.
- Nijhuis I.J., Kok-Van Rooij G.W., Bosschaart A.N., Withdrawal reactions of a premature neonate after maternal paroxetine (letter), *Arch Dis Child Fetal Neonatal Ed* 2001 January, 84 (1): F77-78.
- Noonan D., Cowley G., Prozac vs. placebo, *Newsweek*, 15 July 2002, 48-49.
- Nordeng H., Lindemann R., Perminov K.V., Reikvam A., Neonatal withdrawal syndrome after *in utero* exposure to selective serotonin reuptake inhibitors, *Acta Paediatr*, 2001, 90, 288-291.
- Norton C., Spare your blushes: doctors create pill to stop shyness, *The Sunday Times* (London), 4 October 1998.

- Nuland S.B., The pill of pills, *New York Review of Books*, 9 June 1994, 4-6.
- Nuss S., Kinkaid C.R., Serotonin discontinuation syndrome: does it really exist? *W V Med J*. 2000 Mar-Apr; 96 (2): 405-7.
- Nutt D.J., Addiction: brain mechanisms and their treatment implications. *Lancet* 1996; 346, 31-36.
- J. O'Dwyer's Newsletter, Internet ed. <http://www.odwyerpr.com> - 10 July 2002, p 1
- Oca M.J. et al., Association of maternal sertraline (zoloft) therapy and transient neonatal nystagmus, *J. Perinat*, 1999, 19, 6, 460-461.
- Oehrberg S., Christiansen P.E., Behnke K., Borup A.L., Severin B., Soegaard J., Calberg H., Judge R., Ohrstrom J.K., Manniche P.M., Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study, *Brit. J. Psychiatry*, 1995, 167, 374-379.
- OHE - Office of Health Economics, *Medicines which affect the mind* (London: OHE, 1975).
- OTG - Office of the Inspector General, US Department of Health and Human Services.
- Olver J.S., Burrows G.D., Norman T.R., Discontinuation syndromes with SSRIs. Are there clinically relevant differences? *CNS Drugs*, 1999, 12, 171-177.
- Office of the Inspector General, US Department of Health and Human Services: *FDA's Review Process for New Drug Applications, A Management Review*, OEI-01-0100590, March 2003.
- Opler L.A., Bialkowski C., *Prozac and Other Psychiatric Drugs*, New York: Pocket Books, 1996.
- Oswald I., Drugs and sleep, *Pharmacological Reviews*, 1968, 20 (4), 273-303.
- Lewis S.A., Dunleavy D.L.F. et al., Drugs of dependence though not of abuse: fenfluramine and imipramine. *Brit. Med. J.*, 1971, 10 July, 70-73.
- Pacheco L., Malo P., Aragues E., Etxebeste M., More cases of paroxetine withdrawal syndrome, *Brit J Psychiatry*, Sept 1996, 169 (3), 384.
- Palmer J.L., Postoperative delirium indicating an adverse drug interaction involving the SSRI, paroxetine, *J. Psychopharmacol* 2000 June, 14 (2), 186-188.
- Pare C.M.B., Treatment of depression, *Lancet*, 1 May 1965, 923-925.
- Parker G., Blennerhassett J., Withdrawal reactions associated with venlafaxine. *Aust NZ J Psychiatry* 1998 April, 32:2, 291-4.
- Parish P.A., Williams W.M., Elmes P.C. (eds), The Medical Use of Psychotropic Drugs, report of a symposium held at University College, Swansea, 1-2 July, 1972. Parry V., The art of branding a condition, *Medical Marketing & Media*, May 2003, 43-49.
- Parssinen T.M., Kerner K., Development of the disease model on drug addiction in Britain, 1870-1926, *Medical History*, 1980, 24, 275-296.
- Patris M., Bouchard J.-M., Bougerol T., Charbonnier J.-F., Chevalier J.-F., Clerc G., Cyran C., van Amerongen P., Lemming O., Hopfner Petersen H.E., Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice, *Int. Clin. Psychopharmacol* (1996), 11, 129-136.
- Paykel E.S., Priest R.G., Recognition and management of depression in general practice: consensus statement, *Br. Med. J.*, 14 November 1992, 305, 1198-1202.
- PDUFA - Prescription Drug User Fee Act - FDA and public stakeholders public meeting, Washington DC, DHHS (PHS, FDA), 15 September 2000.
- Peeters F.P.M.L., Zandbergen J., Violent withdrawal symptoms with fever while tapering off paroxetine (In Dutch, with English abstract); *Ned. Tijdschr. Geneesk.*, 1999, 3 July, 143 (27).
- Pekkanen J., *The American Connection*, Chicago, Follett Publishing, 1973.
- Peletier S., Pharma feels the heat, *Association Meetings*, 1 August 2002.
- Petersen M., Madison Avenue plays growing role in drug research, *New York Times*, 22 November 2002.
- Petursson H., Lader M.H., Withdrawal from long-term benzodiazepine treatment, *Br Med J* 1981, 28, 643-645.
- Pfizer Forum, 1998. See [www.pfizerforum.com/authors/elgiebio.shtml](http://www.pfizerforum.com/authors/elgiebio.shtml)
- Phillips S.D., A possible paroxetine withdrawal syndrome. *Am J Psychiatry* 1995, 152 (4), 645-6.
- Physicians' Desk Reference*, 50th edition, Montvale, NJ: Medical Economics Co, 1996.
- Piasecki M.P., Antonuccio D.O., Steinagel G.M., Kohlenberg B.S., Kapadar K., Penetrating the blind in a study of an SSRI, *J. Behav Ther and Exper Psychiatry*, 2002, 33, 67-71.
- Pichot P., The discovery of chlorpromazine and the place of psychopharmacology in the history of psychiatry, interview with D. Healy in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 14.
- PiCTF - Pharmaceutical Industry Competitiveness Task Force, first report, UK Department of Health, March 2001.
- Pincus H.A., Tanielian T.L., Marcus S.C., Olsson M., Zarin D.A., Thompson J., Zito J.M., Prescribing trends in psychotropic medications, *JAMA*, 18 February 1998, 279 (7), 526-531.
- Pinzani V., Ginies E., Robert L., Peyriere H., Abbar M., Blayac J.P., Syndrome de sevrage de la venlafaxine: a propos de six cas et review de la literature, *Rev. Med. Interne*, 2000, 21, 282-294.
- Pippard J., Audit of electroconvulsive treatment in two NHS regions, *Brit. J. Psychiatry*, 1992, 160, 621-637.
- Pirmohamed M., Breckenridge A.M., Kitteringham N.R., Park B.K., Adverse drug reactions, *Brit Med J*, 25 April 1998, 316, 1295-1298.
- Plewes J.M., Koke S.C., Saylor M.E., Adverse events and treatment discontinuations in fluoxetine clinical trials: an updated meta-analysis. *European Neuropsychopharmacology*, 7, S169, 1997.
- Pollock B.G.: Discontinuation symptoms and SSRIs (letter), *J Clin Psychiatry*, 1998, Oct, 59: 10, 535-537.
- Pomerantz J.M., A case of inappropriate use of patient pharmacy data, *Drug Benefit Trends*, 2000, 12 (1), 2, 6.
- Porter A.M.W., Depressive illness in a general practice. A demographic study and a controlled trial of imipramine, *Brit. Med. J.*, 28 March 1970, 773-778.
- Preskorn S.H., Update on antidepressant therapy, *J Clin Psychiatry* 1994 Sept., 55, 9 (suppl A), 3-5.
- in discussion of the natural history and heterogeneity of depressive disorders: Implications for rational antidepressant therapy, *J Clin Psychiatry* 1994 Sept., 55, 9 (suppl A), 32-33.
- Price J.S., Waller P.C., Wood S.M. (Medicines Control Agency), Mackay A.V.P. (Committee on Safety of Medicines), Comparison of the post-marketing safety profiles of fluoxetine, fluvoxamine, paroxetine and sertraline using spontaneous adverse drug reaction reporting, *Pharmacoepidemiol. & Drug Safety*, 4, Suppl. 1, S62 (Abstract from the 11th International Conference on Pharmacoepidemiology, Montreal, Canada, 27-30 August, 1995).

- A comparison of the post-marketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal, *Br. J. Clin. Pharmacol.*, 1996, 42, 757-763.
- Price J.S., (Medicines Control Agency), Letter to Social Audit, 15 September 1997.
- Priest R.G., It's only a cry for help, *World Medicine*, 15 August 1979, 27-30.
- Improving the Management and Knowledge of Depression. *Brit J Psychiatry* 1994, 164, 285-287.
- Recent clinical development with reversible and selective amine oxidase inhibitors: A valuable addition to the armamentarium, Chairman's Introduction. *J Clin Psychopharmacol* 1995, 15 (4 suppl. 2), 1S-3S.
- Vize C., Roberts A., Roberts M., Tylee A., Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch, *Brit. Med. J.*, 5 October 1996, 313, 858-859.
- Prosser H., Almond S., Whalley T., Influences on GPs' decision to prescribe new drugs – the importance of who says what, *Family Practice*, 2003, 20, 1, 61-68.
- Public Citizen, *Rx & D Myths: the Case against the Drug Industry's R&D "Scare Card"*, (Washington DC), 23 July 2001.
- Pye R.E., Paroxetine withdrawal syndrome. *Am J Psychiatry* 1995 Jan, 152 (1), 149-150.
- Quintiles Press Release, July 9 2001, Rx's and RSV's: Pharmaceutical companies holding more physician events and meetings, seen 15 October 2002 at [www.quintiles.com/product\\_and\\_services/informatics/scot/levin/press\\_release/2001\\_archives](http://www.quintiles.com/product_and_services/informatics/scot/levin/press_release/2001_archives).
- Raach J.H., book review of Ayd F.J., *Recognising the depressed patient*, *JAMA*, 21 Oct 1961, 178 (3), 357.
- Raby W.N., Treatment of venlafaxine discontinuation symptoms with odansetron (letter), *J Clin Psychiatry*, 1998, Nov, 59(11), 621-622.
- Rajagopalan M., Little J., Discontinuation symptoms with nefazodone, *Aust & NZ J. Psychiatry*, 1999, 33, 594-597.
- Rapport D.J., Calabrese J.R., Tolerance to fluoxetine. *J Clin Psychopharmacol* 1993 Oct, 13 (5), 361.
- Rauch S.L., O'Sullivan R.L., Jenike M.A., Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases, *J. Clin Psychopharmacol.*, Feb 1996, 16 (1), 81-84.
- Rawlins, M.D., letter to *Social Audit*, 14 July 1987.
- Rawlins M.D. (Chair, Committee on Safety of Medicines, 1993-2000), letter to Social Audit, 8 May 1998.
- RCP/RCGP – Royal College of Psychiatrists, Royal College of General Practitioners, Defeat Depression Campaign press release: MORI poll reveals public confusion about antidepressants and tranquillisers: "Antidepressants not addictive", says Defeat Depression Campaign. London: RCP & RCGP, 1992.
- RCP – Royal College of Psychiatrists, Twenty-Third Annual Report, London: RCP, 1996.
- Press pack for Defeat Depression Action Week, 3-11 March 1994.
- Redwood H., *The Pharmaceutical Industry – Trends, Problems and Achievements* (Felixstowe, Suffolk: Oldwicks Press, 1997).
- Pharmapolitics 2000 – Key issues for the industry, Richmond, Surrey, *SCRIP Reports*, 1997).
- Reeves R.R., Pinkofsky H.R., Lhermitte's Sign in paroxetine withdrawal, *J. Clin. Psychopharmacol.*, 16, 5, October 1996, 411-412.

- Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., Beasley C.M., Michelson D., Roback P., Sundell K., Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment: *Am J Psychiatry*, 1998, September, 155, 9, 1247-1253.
- Relman A.S., Angell M., America's other drug problem, *The New Republic*, 16 December 2002, 27-41.
- Reus V.I., Management of Treatment-Resistant Unipolar and Chronically Depressed Patients, in M. Hornig-Rohan, J.D. Amsterdam J.D. (eds), *Treatment-Resistant Depression*, The Psychiatric Clinics of North America, June 1996, 19 (2), 201-213.
- Reynolds J.E.F. (ed.), *Martindale The Extra Pharmacopoeia*, 31st Ed., London: Royal Pharmaceutical Society, 1996, 299.
- Rickels K., Downing R., Schweitzer E., Hassman H., *Archives of General Psychiatry*, 1993, 50, 884-895.
- Rimer S., With millions taking Prozac, a legal drug culture arises, *New York Times*, 13 December 1993, A1-B8.
- Roberts I., Li Wan Po A., Chalmers I., Intellectual property, drug licensing, freedom of information and public health, *Lancet* 1998, 352, 726-729.
- Roberts D.T., Taylor W.D., Boyle J., British Association of Dermatologists, Guidelines for treatment of onychomycosis, *Br J Dermatol.* 2003 Mar; 148 (3): 402-10.
- Rochon P.A., Berger P.B., Gordon M., The evolution of clinical trials: inclusion and representation, *CMAJ*, 1998, 159, 1373-1374.
- C. Rojas-Fernandez, J. Gordon: Selective serotonin reuptake inhibitor discontinuation syndrome: putative mechanisms and prevention strategies (letter), *Can J Psychiatry*, 1998, June, 43(5), 523-524.
- Rosenbaum J., Risk of Adverse Events and Depressive Symptom Breakthrough Following Brief Interruption of SSRI therapy, pp 555-557. In Thompson C, chairperson, Discontinuation of Antidepressant Therapy: Emerging Complications and Their Relevance (ACADEMIC HIGHLIGHTS), *J. Clin Psychiatry*, 1998, 59, 541-548.
- Rosenbaum J.F., Fava M., Hoog S.L., Ascroft R.C., Krebs W.B., Selective Serotonin Reuptake Inhibitor discontinuation syndrome: A randomised clinical trial, *Biol Psychiatry*, 1998, 44, 77-87.
- Rosenblat J.E., Toxicology and drug interactions: two more cases of fluoxetine withdrawal (and SSRI withdrawal symptoms online), *Currents in Affective Illness*, 1994, 13, 11, 15-17.
- Rosenstock H.A., Sertraline withdrawal in two brothers: a case report. *Int Clin Psychopharmacol* 1996 Mar, 11 (1), 58-9.
- Ross W., It's no FDA but it works, *Medical Marketing and Media*, August 2000.
- Rothman D., That Prozac moment, *The Guardian* (Review), 4 February 1994, 2-4.
- Roy A., Virkkunen M., Linnoila M., Serotonin in Suicide, Violence, and Alcoholism, in Coccaro E.F., Murphy D.L. (eds), *Serotonin in Major Psychiatric Disorders*, Washington DC, American Psychiatric Press, 1990, 187-208.
- Rudolph R.L., Fabre L.F., Feighner J.P. et al., A randomised placebo-controlled dose-response trial of venlafaxine hydrochloride in the treatment of major depression, *J. Clin Psychiatry*, 1998, 59, 116-122.
- Sackville T. (UK Minister of State for Health), Medicines Information Bill, *Hansard*, Standing Committee C, 24 February 1993, 48.

- Sager, A., Socolar D., Drug Industry Marketing Staff Soar While Research Staff Stag-  
nates, Health Reform Program, Health Services Department, Boston University  
School of Public Health, Brief dated 6 December 2001. <http://dcc2.bumc.bu.edu/hs/ushealthreform.htm>
- Sainsbury Lord (Chairman), Report of the Committee of Enquiry into the Relationship  
of the Pharmaceutical Industry with the National Health Service, 1965-1967. Cmd.  
3410, London: HMSO, 1967.
- Sargent W. (discussant in conference proceedings), Depression, *Lancet*, 3 October 1959,  
509-511.
- Drugs in the treatment of depression, *Brit Med. J.*, 28 January 1961, 225-227.
- Discussant in Parrish et al., (eds), 1972.
- Dally P., Treatment of anxiety states by antidepressant drugs, *Brit. Med. J.*, 6 Jan,  
1962, 6-9.
- Sartorius N., Depressive Illness as a Worldwide Problem, in P. Kielholz (ed.), Bern:  
Hans Huber, 1974.
- Depressive disorders – a major public health problem, in Ayd F. (ed.), *Mood Dis-  
orders: The World's Major Public Health Problem*, Baltimore: Ayd Medical Communi-  
cations, 1978.
- Schatzberg M., Haddad P., Kaplan E.M., Lejoyeux M., Rosenbaum J.F., Young A.H.,  
Zajecka J., Antidepressant Discontinuation Syndrome: update on serotonin reuptake  
inhibitors, *J Clin Psychiatry*, 1997, 58 (suppl 7), 1-4.
- Schirm E., Tobi H., Zito J.M., de Jong-van den Berg L.T., Psychotropic medication in  
children: a study from the Netherlands, *Pediatrics*, 2001 Aug, 108 (2), E25.
- Schofield I., Committees, careers and corruption, *Scrip Magazine*, November 1993, 41-44.
- Sclar D.A., Robinson L.M., Skaer T.L., Galin R.S., Trends in the prescribing of anti-  
depressant pharmacotherapy: office-based visits, 1990-1995. *Clin Ther* 1998 Jul-Aug  
20:4 871-84; 870.
- Scottowe I., Drugs in the treatment of depression, *Lancet*, 1955 May 8, 1129.
- SCRIP – (Anon), Norway rejects fluoxetine on appeal, *SCRIP* No 1618, 22 May 1991, 26.
- (Anon), Lilly attacks Prozac hype, *SCRIP* No 1913, 12 April 1994, 11.
- (Anon), US DTC campaigns – Caverject, Effexor, *SCRIP* No 2208, 21 February 1997, 14.
- (Anon) Update for EU advertising rules, *SCRIP* No 2378, 14 October 1998.
- (Anon) European Commission *SCRIP* No 2712, 16 January 2002, p. 3.
- Seglin J.L., Just saying No to gifts from drug makers, *New York Times*, 18 August 2002.
- Sempere E., Martinez I., Martinez-Mir I., Rey A., Withdrawal syndrome and citalopram  
(letter, in Spanish) *Med Clin (Barc)* 2000 March 11, 114 (9): 359.
- Senn S., Are placebo run ins justified? *Brit. Med. J.*, 19 April 1997, 314, 1191-1193.
- Sharkey S. Morphinomania, *Nineteenth Century*, 1887, 22, 335-342.
- Sharma V., Loss of response to antidepressants and subsequent refractoriness: diagnostic  
issues in a retrospective case series, *J Affective Disorders*, 2001, 64, 99-106.
- Shatin D., Drinkard C.R., Ambulatory use of psychotropics by employer-insured chil-  
dren and adolescents in a national managed care organization, *Ambul Pediatr*, 2002,  
Mar-Apr; 2 (2), 111-119.
- Shelton D.L., Mistaking medicine, *AMNews*, 21 September 1998.
- Sheldon T., How whistleblowing cost one doctor £550,000, *Brit Med J*, 324, 25 May  
2002, 1240.
- Drug company employee who queried trial wins appeal, *Brit Med J*, 327, 9 August  
2003, 307.
- Shoenberger D., Discontinuing paroxetine: a personal account, *Psychother Psychosom*,  
2002, 71, 237-238.
- Shopsin B., Cassano G.B., Conti L., An Overview of New 'Second Generation' Anti-  
depressant Compounds: Research and Treatment Implications, in Enna S.J., Malick  
J.B. & Richelson E. (eds), *Antidepressants: Neurochemical, Behavioural, and Clinical  
Perspectives* [New York, Raven Press, 1981], 219 – 251.
- Shorter E., *A History of Psychiatry – From the Era of the Asylum to the Age of Prozac*. To-  
ronto, John Wiley & Son, 1997.
- Shriver A.E., Sachs G.S. et al., Mania and hypomania following antidepressant discon-  
tinuation, in New Research Program and Abstracts, Abstract NR 161: 111, American  
Psychiatric Association, 151st Annual Meeting, Toronto, June 1998.
- Sierra Santos L., Raigal Marin Y., Ortega Carcia A., Berriochoa Martinez de Pison C.,  
Aparicio Jabalquinto G., Venlafaxina y síndrome de discontinuación, *Atencion Pri-  
maria*, December 1999, 24 (10), 115-116.
- Sigelman D.W., Dangerous medicine, *The American Prospect*, 23 September 2002, 13, 17.
- Silverstein K., Prozac.org, *Mother Jones*, December 1999.
- Silvestri R., Pace-Schott E.F., Gersh T., Stickgold R., Salzman C., Hobson J.A., Effects  
of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based  
Nightcap evaluation during drug administration and withdrawal, *J Clin Psychiatry*,  
2001 Aug, 62, 8, 642-652.
- Sims A.C.P. (President, Royal College of Psychiatrists), Unpublished correspondence,  
6 February 1992.
- Sindrup S.H., Brosen K., Gram L.F., Pharmacokinetics of the selective serotonin  
reuptake inhibitor of paroxetine: nonlinearity and relation to the sparteine oxidation  
polymorphism. *Clin. Pharmacol. Ther.*, 1992, 5, 3, 288-295.
- Skottowe I., Drugs in the treatment of depression, *Lancet* 1955, May 8, 1129.
- Smith A., Traganza E., Harrison G., Studies on the effectiveness of antidepressant drugs.  
*Psychopharmacology Bulletin*, (Special issue), March 1969, 1-53.
- Smith R., Review: *Limits to medicine. medical nemesis: the expropriation of health* (Ivan  
Illich), *Brit Med J*, 2002 April 13, 324, 923.
- Song F., Freemantle N., Sheldon T.A., et al., Selective serotonin reuptake inhibitors:  
meta-analysis of efficacy and acceptability. *Brit Med J* 1993, 306, 683-7.
- Spencer M.J., Fluoxetine hydrochloride (Prozac) toxicity in a neonate. *Pediatrics* 1993  
Nov, 92 (5), 721-2.
- Spijker J., de Graaf R., Bijl R.V., Duration of major depressive episodes in the general  
population: results from the Netherlands mental health survey and incidence study  
(NEMESIS), *Br. J. Psychiatry*, 2002, 181, 208-212.
- Stahl M.M.S., Lindquist M., Pettersson M., Edwards I.R., Sanderson J.H., Taylor N.F.,  
Withdrawal reactions with selective serotonin reuptake inhibitors (SSRIs) as reported  
to the WHO system, *Eur. J. Clin. Pharmacol.*, 1997; 53 (3-4): 163-9.
- Stein M.B., Chartier M.J., Hazen A.L., Kroft C.D.L., Chale R.A., Coré D., Walker J.R.,  
Paroxetine in the treatment of generalised social phobia: open-label treatment and  
double-blind placebo-controlled discontinuation, *J. Clin Psychopharmacol*, 16 (3),  
June 1996, 218-222.
- Stevens J., Hypnotics – A GP's view, *Prescribers Journal*, October 1973, 13 (5), 102.

- Stewart J.W., Quitkin F.M., McGrath P.J., Amsterdam J., Fava M., Fawcett J., Reimherr F., Rosenbaum J., Beasley C., Roback P., Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo: *Arch Gen Psychiatry*, 1998, September, 55, 334-443.
- Stiskal J.A., Kulin N., Koren G., T. Ho, S. Ito, Neonatal paroxetine withdrawal syndrome (short report of four cases), *Arch Dis Child Fetal Neonatal Ed*, 2001, 84, F134-F135. See comment (and author's response) by Ibister et al in *Arch Dis Child Fetal Ed*, 2001, Sept, 85(2), F147-148.
- Stoukides J.A., Stoukides C.A., Extrapyramidal symptoms upon discontinuation of fluoxetine, *Am. J. Psychiatry*, 1991 September, 148, 9, 1263.
- Strickland G.M., Hough D.W., Unilateral facial numbness and visual blurring associated with paroxetine discontinuation (letter), *J Clin Psychopharmacol* 2000 April, 20 (2), 271-272.
- Suppes T., Baldessarini R.J., Motohashi N., Tondo L., Viguera A.C., Special treatment issues: maintaining and discontinuing psychotropic medications. *Mod Probl Pharmacopsychiatry* 1997, 25, 235-254.
- Swiatek J., New rules limit drug reps, *Indianapolis Star*, 16 October 2002.
- Szabadi E., Fluvoxamine withdrawal syndrome. *Brit J Psychiatry* 1992 Feb, 160, 283-284.
- Tamam A., Ozpoyraz N., Selective serotonin reuptake *Adv Ther*, 2002 Jan-Feb, 19, 1, 17-26.
- Taylor D., Truth withdrawal, *Open Mind* (National Association for Mental Health), September/October 1999, 16.
- Teicher M.H., Glod C.A., Cole J.O., Antidepressant drugs and the emergence of suicidal tendencies, *Drug Safety*, 1993, 8, 3, 186-212.
- Temple R. (FDA), Deposition, 4 September 2002, in Re Paxil litigation, CV-01-07937 MRP (CWx).
- Terao T., Misdiagnosis of antidepressant discontinuation symptoms, *Acta Psychiatr Scand*, 2001 104(1), 77-78.
- Thase M.E. (for the Venlafaxine XR209 Study Group), Efficacy and tolerability of once-daily Venlafaxine Extended Release (XR) in outpatients with major depression, *J Clin Psychiatry*, September 1997, 58 (9), 393-398.
- Therrien F., Markowitz J.S., Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature, *Human Psychopharmacology*, 1997, 12, 309-323.
- Thomas K.B., The placebo in general practice. *Lancet*, 1994 Oct 15; 344, 1066-7.
- Thomas L., The health-care system, in *The Medusa and the Snail - more notes of a biology watcher*, New York: Bantam, 1979.
- *Late Night Thoughts on Listening to Mahler's Ninth Symphony*, New York, Viking, 1983.
- *The Youngest Science*, Notes of a Medicine-Watcher, New York, Viking, 1983.
- In Briggs A., Shelley J. (eds), *Science, Medicine and the Community: The Last Hundred Years*, Amsterdam: Excerpta Medica, 1986, 19.
- Thompson C., Discontinuation of antidepressant therapy: emerging complications and their relevance. *J Clin Psychiatry* 1998 Oct, 59:10, 541-8.
- Thompson L., Memorandum 7/2/90, *Forsyth v Eli Lilly*, Plaintiff's exhibit 98, 1990-1999, cited in Healy (1999).
- Tollefson G.D., Adverse drug reactions/interactions in maintenance therapy. *J Clin Psychiatry* 1993 Aug, 54 (8 Suppl), 48-58.
- Toop L., Richards D., Dowell T., Tilyard M., Fraser T., Arroll B, *Direct to Consumer Advertising of Prescription Drugs in New Zealand - For Health Or Profit?* Report to the Minister of Health supporting the case for a ban on DTCA (New Zealand Departments of General Practice, Dunedin, Wellington and Auckland Schools of Medicine, February 2003).
- Torrey E.F., *The Mind Game - Witchdoctors and psychiatrists*, New York: Emerson Hall, 1972.
- Toufexis A., The personality pill, *Time*, 11 October 1993, 53-54.
- Toynbee P., *Radio Times*, 13-19 August, 1995, p 22.
- Tracey A.B., *Prozac - Panacea or Pandora?* Salt Lake City, Cassia Publications, 1994.
- Tranter R., Healy D., Neuroleptic discontinuation syndromes, *Journal of Psychopharmacology*, 1998, 12 (3), 306-311.
- Trenque T., Piednoir D., Frances C., Millart H., Germain M.L., Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database. *Pharmacoepidemiol Drug Saf*, 2002 Jun, 11, 4, 281-283.
- Tufts Center for the Study of Drug Development pegs cost of a new prescription medicine at \$802 million, Press Release dated 30 November 2001.
- Turkington C., Kaplan E.F., *Making the Prozac Decision - A Guide to Antidepressants*, Los Angeles: RGA Publishing Group, 1995.
- Tyrer P., Rutherford H.D., Hugget T., Benzodiazepine withdrawal symptoms and propranolol. *Lancet*, 7 March 1981, 520-522.
- Tyrer P., Stress diathesis and pharmacological dependence, (comment on Healy and Tranter, 1999) *J Psychopharmacol*, 1999, 13 (3), 294-295.
- US Congress: Subcommittee on Oversight and Investigations of the House of Representatives Committee on Energy and Commerce: *Prescription Drug Advertising to Consumers*. Washington: GPO, September (1984).
- US FTC: Generic Drug Entry Prior to Patent Expiration, Washington DC: Federal Trade Commission, July 2002.
- US Food and Drug Administration, Center for Drug Evaluation and Research: Sample written request for antidepressants (re: requirements for safety, efficacy and other studies relating to treatment of pediatric depression), 10 September 1999. See: [http://www.fda.gov/cder/pediatric/antidepressant\\_wr\\_template.htm](http://www.fda.gov/cder/pediatric/antidepressant_wr_template.htm)
- VandeHei J., Eilperin J., Drug firms gain church group aid, *Washington Post*, 23 July 2003, page A01.
- Van Grootheest K., De Graaf L., de Jong-van den Berg L.T.W., Consumer adverse drug reaction reporting: a new step in pharmacovigilance? *Drug Safety*, 2003; 26 (4): 211-217.
- Van Noorden M.S., Vergouwen A.C., Koerselman G.F., (In Dutch - Re: delirium in venlafaxine withdrawal), *Ned Tijdschr Geneesk*, 2002, June 29, 146, 26, 1236-1237.
- Van Praag H., Psychiatry and the march of folly?, interview with D. Healy in *The Psychopharmacologists*, London: Chapman & Hall (Altman), 1996, 367.
- Veash N., 'Miracle' smoking cure cuts craving, *The Observer*, 11 July 1999.
- Vedantam S., Drug ads hyping drug ads make some uneasy, *Washington Post*, 16 July 2001, A01.
- Venning G., Antidepressant drugs have previously been shown to be ineffective in mild depression, *Brit. Med. J.*, 29 January 2000, 320, 311.
- Vergouwen A.C., Kuipers T., Severe withdrawal symptoms with fever upon stopping paroxetine (letter, in Dutch), *Ned Tijdschr Geneesk*, 28 August 1999, 143 (35), 1794-5, discussion 1795-6.



- Viguera A.C., Baldessarini R.J., Friedberg J., Discontinuing antidepressant treatment in major depression, *Harvard Rev Psychiatry*, 1998, 5, 293-306.
- Wade G.S., Controlled withdrawal for psychotropic drugs, *Lancet* 2000 May 20, 355 (9217); 1822-1823.
- Wagner K.D., Ambrosini P., Rynn M., Wohlberg C., Yang R., Greenbaum M.S., Childress A., Donnelly C., Deas D., for the Sertraline Pediatric Depression Study Group: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder, *JAMA*, 2003, August 27, 290, 8, 1033-1041.
- Walker-Kinnear M., McNaughton S., Paroxetine discontinuation syndrome in association with sertindole therapy, *Brit J Psychiatry*, April 1997, 170, 389.
- Wall Street Journal (Editorial), Europe's addiction, 2 January 2002.
- Waller P.C., Wood S.M., Langman M.J.S., Breckenridge A.M., Rawlins M.D., Review of company post-marketing surveillance studies, *Brit Med J*, 6 June 1992, 304, 1470-1472.
- Waller P.C., Evans S.J.W., A model for the future conduct of pharmacovigilance. *Pharmacoepidemiology and Drug Safety*, 2003; 12, 17-29.
- Walters J., Prozac research targets local girls, *The Hamilton Spectator*, 2 November 2002.
- Warner J., Outlook: Glaxo's Garnier struggles under mountain of patent lawsuits, *The Independent*, 24 October 2002.
- Washington Post (Editorial) Big drug makers' tactics, 16 September 2002, A18.
- Wayne L., Petersen M., A muscular lobby tries to shape the nation's bioterror plan. *New York Times*, 4 November 2001.
- Wells F.O., Prescribing barbiturates: drug substitution in general practice, *J. Roy Coll Gen Practit*, 1973, 23, 164.
- Wernicke J.F., Dunlop S.R., Dornseif B.E., Bosomworth J.C., Humbert M., Low-dose fluoxetine therapy for depression, *Psychopharmacology Bulletin*, 1988, 24: 183-188.
- Wheadon D., broadcast statements (on behalf of SmithKline Beecham Pharmaceuticals and GlaxoSmithKline) relating to paroxetine (Paxil®) withdrawal, on the '20-20' programme, *A Painful Withdrawal*, ABC TV, 25 August 2000.
- Wingate P., Wingate R., *Medical Encyclopedia*, (4th edition), London: Penguin, 1996.
- World Health Organization – Expert Committee on Drugs liable to produce addiction – report of the second session, (Technical Report Series No 21), Geneva: World Health Organization, 1950.
- WHO Expert Committee on Drug Dependence. 13th report, TRS No 273. Geneva: World Health Organization, 1964.
- Expert Committee, *The Selection of Essential Drugs* TRS 615, Geneva: WHO, 1977
- Expert Committee, *New Approaches to health education in primary health care*, WHO, Geneva, 1983.
- *The International Classification of Diseases, ICD-10, Classification of Mental and Behavioural Disorders, clinical descriptions and diagnostic guidelines*. Geneva: WHO, 1992.
- 28th report, WHO Technical Report Series No 836. Geneva: WHO, 1993.
- *Lexicon of alcohol and drug terms*, Geneva, World Health Organization, 1995. 28.
- (Anon), Selective serotonin re-uptake inhibitors and withdrawal reactions, *WHO Drug Information*, 1998, 12, 3, 136-138.
- Uppsala Monitoring Centre: print out of drugs most reported to cause withdrawal problems indicative of dependence, dated 27 January 2001. (Extract lists drugs for which 100 or more reports have been received).
- Report of the Commission on Macroeconomics and Health, *Macroeconomics and Health: Investing in Health for Economic Development*, 2002.
- WHO Expert Committee on Drug Dependence, 33rd Report (TRS 915), Geneva, 2003.
- Wincor M.Z., Withdrawal symptoms associated with abrupt discontinuation of SSRIs, *J Am Pharm Assoc (Wash)*, 1998, July-August, 38(4), 500-501.
- Wise J., ECT clinics are below standard, *Brit. Med. J.*, 25 January 1997, 314, 248.
- Wise P., Drury M., Pharmaceutical trials in general practice: the first 100 protocols. An audit by the clinical research ethics committee of the Royal College of General Practitioners, *Brit. Med. J.*, 16 November 1996, 313, 1245-1248.
- Wisner K.L., Gelenberg A.J., Leonard H., Zarin D., Frank E., Pharmacologic treatment of depression during pregnancy, *JAMA*, 6 October 1999, 282 (13), 1264-1269.
- Wolpert L., *Malignant Sadness – The anatomy of depression*, London: Faber and Faber, 1999.
- Wurtzel E., *Prozac Nation: Young and depressed in America*, London: Quartet, 1996.
- Yamey G., Drug industry writers propose code of ethical conduct, *Brit Med J*, 2002 April 6, 324, 808.
- Yapp P., Ilett K.F., Kristensen J.H., Hackett L.P., Paech M.J., Drowsiness and poor feeding in breast-fed infant: association with nefazodone and its metabolites, *Ann Pharmacother* 2000 Nov, 34 (11), 1269-1272.
- Young A.H., Currie A., Physicians' knowledge of antidepressant withdrawal effects: a survey, *J Clin Psychiatry*, 1997, 58 (suppl 7), 28-30.
- Young A., Haddad P., Discontinuation symptoms and psychotropic drugs (letter): *Lancet*, 355, 1 April 2000, 1184.
- Zajacka J., Tracy K.A., Mitchell S., Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review, *J Clin. Psychiatry*, July 1997, 58, 7, 291-297.
- Zajacka J., Fawcett M.D., Amsterdam J., Quitkin F., Reimherr F., Rosenbaum J., Michelson D., Beasley C., Safety of abrupt discontinuation of fluoxetine: A Randomised, Placebo-Controlled Study, *J. Clin Psychopharmacol.*, 1998, 18, 3, 193-197.
- Zimmerman M., Posternak M.A., Chelminsky I., Symptom severity and exclusion from antidepressant efficacy trials, *J Clin Psychopharmacol*, 2002 Dec, 22, 6, 610-614.
- Mattia J.I., Posternack M.A., Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?, *Am J Psychiatry*, 2002, March, 159, 3, 469-473.
- Zito J.M., Safer D.J., DosReis S., Gardner J.F., Boles M., Lynch F., Trends in the prescribing of psychotropic medications to preschoolers, *JAMA*, 23 February 2000, 283(8), 1025-1030.
- Zito J.M., Safer D.J., DosReis S., Gardner J.F., Soeken K., Boles M., Lynch F., Rising prevalence of antidepressants among US youths, *Pediatrics* 2002 May; 109(5):721-7.
- Zito J.M., Safer D.J., DosReis S., Gardner J.F., Magder L., Soeken K., Boles M., Lynch F., Riddle M.A., Psychotropic practice patterns for youth: a 10-year perspective, *Arch Pediatr Adolesc Med* 2003 Jan; 157 (1): 17-25.
- Zubenko G.S., Cohen B.M., Lipinski J.F., Antidepressant-related akathisia, *J. Clin. Psychopharmacology*, 1987, 7, 254-257.



## Glossary

### Drug names and identification

Medicines may be described either by the 'generic' name – which identifies the drug itself – and/or with a brand name, which identifies a particular manufacturer's version of the drug. Regulatory requirements mean there should be no significant difference between different manufacturers' versions of the same drug.

Generic drug names are mostly internationally standardised, but occasionally, different countries apply different generic names – e.g. amfebutamone (us) = bupropion (uk); and acetaminophen (us) = paracetamol (uk). However, the identification by brand name can get complicated – e.g. when the manufacturer uses different brand names in different countries, to describe the same drug – or when the same drug is supplied under different brand names, for different applications. For example, Glaxo- SmithKline sells the same drug, paroxetine, as Paxil (us), Seroxat (uk) and Aropax (Aus). In the us, Eli Lilly & Co sells the drug, fluoxetine, both as Prozac (for depression) and as Sarafem (for severe menstrual disorders).

During the period of patent protection, which typically lasts for about ten years after a drug is first introduced, brand names predominate. When a drug comes off patent, allowing other manufacturers to produce the originally patented drug, brand names tend to give way to generic names. The main drugs mentioned in this book are:

alprazolam = Xanax®  
 amfebutamone = bupropion  
 amitriptyline = a tricyclic antidepressant  
 Aropax® = paroxetine  
 Ativan® = lorazepam  
 atomoxetine = Strattera®  
 benoxaprofen = Opren®  
 bupropion = Zyban®, Wellbutrin®  
 Celexa® = citalopram  
 chloral hydrate = a sedative/hypnotic  
 chlordiazepoxide = Librium®  
 cimetidine = Tagamet®

Cipralex® = (es)citalopram  
 Cipramil® = citalopram  
 Cymbalta® = duloxetine  
 Dalmane® = flurazepam  
 diamorphine = Heroin  
 diazepam = Valium®  
 duloxetine = Cymbalta®  
 Dutonin® = nefazodone  
 Efexor®, Effexor® = venlafaxine  
 Equanil® = meprobamate  
 Faverin® = fluvoxamine  
 fluoxetine = Prozac®, Sarafem®  
 flurazepam = Dalmane®  
 fluvoxamine = Luvox®, Faverin®  
 Halcion® = triazolam  
 Heroin = diamorphine  
 imipramine = a tricyclic antidepressant  
 Lexapro® = (es)citalopram  
 Librium® = chlordiazepoxide  
 Lustral® = sertraline  
 Luvox® = fluvoxamine  
 meprobamate = Miltown®, Equanil®  
 Miltown® = meprobamate  
 Mogadon® = nitrazepam  
 nefazodone = Serzone®, Dutonin®  
 nitrazepam = Mogadon®  
 Opren® = benoxaprofen  
 oxazepam = Serax®, Serenid-D®  
 paroxetine = Paxil®, Seroxat®, Aropax®  
 Paxil® = paroxetine  
 Prozac® = fluoxetine  
 ranitidine = Zantac®  
 Ritalin® = methylphenidate  
 Sarafem® = fluoxetine  
 sertraline = Zoloft®, Lustral®  
 Serzone® = nefazodone  
 Seroxat® = paroxetine  
 Serzone® = nefazodone  
 Tagamet® = cimetidine  
 temazepam = Restoril®  
 triazolam = Halcion®

Wellbutrin® = amfebutamone, bupropion  
 Xanax® = alprazolam  
 Zantac® = ranitidine  
 Zoloft® = sertraline  
 Zyban® = bupropion

### Currency equivalents: £, \$ and €

Significant fluctuations in the relative value of different currencies over the years meant it would not have been realistic to give dual values (£/US\$) in the text. At the time of going to press, US\$1 = £0.58 or €0.83; £1 = US\$1.72 or €1.42; and €1 = US\$1.21 or £0.70.

### Institutional identities and acronyms

ABC	American Broadcasting Corporation
ABPI	Association of the British Pharmaceutical Industry
ADR	Adverse Drug Reaction
ADROIT	Adverse Drug Reactions On-line Information Tracking (UK)
ADWEB	The Antidepressant Web
APA	American Psychiatric Association
ASPP	Anonymised Single Patient Print (anonymised ADR report, UK)
BBC	British Broadcasting Corporation
BMJ	British Medical Journal
BNF	British National Formulary
CFOI	Campaign for Freedom of Information (UK)
CPMP	Committee on Proprietary Medicinal Products (EU)
CRM	Committee on Review of Medicines (UK)
CRO	Clinical research organisation
CSM	Committee on Safety of Medicines (UK)
DG Enterprise	Directorate-General Enterprise (EC)
DOH	Department of Health (UK)
DSM	Diagnostic & Statistical Manual
DTB	Drug & Therapeutics Bulletin
DTC	Direct To Consumer
DTCA	Direct To Consumer Advertising
EC	European Commission
ECDD	Expert Committee on Drug Dependence (WHO)
ECT	Electro-convulsive therapy

EEG	electroencephalogram
EFPIA	European Federation of Pharmaceutical Industry Associations
EMEA	European Medicines Evaluation Agency
EU	European Union
FDA	Food & Drug Administration (US)
G10	Group of Ten (EC-founded pharma competitiveness taskforce)
GCP	Good Clinical Practice
GSK	GlaxoSmithKline
HAI (E)	Health Action International (Europe)
HAM-D	Hamilton depression rating scale
HIV	Human Immunodeficiency Virus
ICH	International Conference on Harmonisation (on technical requirements for registration of pharmaceuticals for human use)
ICMJE	International Committee of Medical Journal Editors
IFPMA	International Federation of Pharmaceutical Marketing Associations
IOM	Institute of Medicine (US National Academy of Sciences)
IRB	Institutional Review Board (US); Ethics Committee (UK)
JAMA	Journal of the American Medical Association
MAOI	Monoamine Oxidase Inhibitor
MCA	Medicines Control Agency (UK)
MEP	Member of the European Parliament
MHD	Mental Health Division (WHO)
MHRA	Medicines and Healthcare products Regulatory Agency (UK)
MIND	National Association for Mental Health (UK)
NAMI	National Alliance for the Mentally Ill (US)
NAO	National Audit Office (UK)
NCE	New Chemical Entity
NEJM	New England Journal of Medicine
NERO defence	'no evidence of risk = evidence of no risk'
NHS	National Health Service (UK)
NICE	National Institute for Clinical Excellence (UK)- performance
NIH	National Institutes of Health (US)
NOS	Not otherwise specified
O/D	Drug overdose
PDUSA	Prescription Drug User Fee Act (US)
PhRMA	Pharmaceutical Research and Manufacturers of America (US)
PICTF	Pharmaceutical Industry Competitiveness Taskforce (UK)
R&D	Research and development
RCGP	Royal College of General Practitioners
RCPS	(RCPSych) Royal College of Psychiatrists

SKB	SmithKline Beecham (GSK from 2000)
SSRI	Selective Serotonin Reuptake Inhibitor
TABD	Transatlantic Business Dialogue (EU-US)
UK	United Kingdom (England, Scotland, Wales, Northern Ireland)
UMC	Uppsala Monitoring Centre (WHO)
WHO	World Health Organization
WPA	World Psychiatric Association
WTO	World Trade Organization
Yellow Card	UK adverse drug reaction report